

5th November 2020

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 Scrip Code: BSE – AJANTPHARM 532331	National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Scrip Code: NSE AJANTPHARM EQ
---	--

Sub: Submission of Public Announcement for buyback of equity shares of Ajanta Pharma Limited (“Company”)

Dear Sir/Madam,

This is further to our intimation dated 3rd November 2020, where the Company has informed that the Board of Directors of the Company have approved the proposal to Buyback fully paid up Equity Shares of the Company from the existing shareholders/ beneficial owners as on Record Date including promoters and members of promoter group on a proportionate basis through the Tender Offer process in accordance with Securities and Exchange Board of India (Buy-Back of Securities) Regulations, as amended (“**Buyback Regulations**”).

In this connection, pursuant to Regulation 7 of Buyback Regulations, please note that today i.e. 5th November 2020, the Company has published the Public Announcement dated 4th November 2020 of Buyback in following newspapers:

Publication	Language	Editions
Business Standard	English	All
Business Standard	Hindi	All
Navshakti	Marathi	Mumbai

The clippings of the said Public Announcement are enclosed for your reference and dissemination on the Stock Exchanges.

Thanking you,

Yours faithfully,

For **Ajanta Pharma Limited**

Gaurang Shah
Digitally signed
by Gaurang Shah
Date: 2020.11.05
12:20:44 +05'30'

GAURANG SHAH*VP – Legal, Corporate Affairs & Company Secretary*

Encl.: a/a



AJANTA PHARMA LIMITED

CIN : L24230MH1979PLC022059

Registered & Corporate Office: 'Ajanta House', 98 Govt Industrial Area, Charkop, Kandivli (West), Mumbai - 400 067, Maharashtra, India
Tel.: +91 22 6606 1000, Fax: +91 22 6606 1200 | E-mail: investorgreivance@ajantapharma.com
Website: www.ajantapharma.com

PUBLIC ANNOUNCEMENT FOR THE ATTENTION OF EQUITY SHAREHOLDERS/ BENEFICIAL OWNERS OF EQUITY SHARES OF AJANTA PHARMA LIMITED FOR BUYBACK OF EQUITY SHARES THROUGH TENDER OFFER UNDER THE SECURITIES AND EXCHANGE BOARD OF INDIA (BUY-BACK OF SECURITIES), REGULATIONS, 2018, AS AMENDED.

This Public Announcement (the "Public Announcement") is being made in relation to the Buyback (as defined hereinafter) pursuant to the provisions of Regulation 7(i) and other applicable provisions of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended (the "Buyback Regulations") for the time being in force including any statutory modifications and amendments from time to time and contains the disclosures as specified in Schedule II to the Buyback Regulations read with Schedule I of the Buyback Regulations.

CASH OFFER FOR BUYBACK OF NOT EXCEEDING 7,35,000 (SEVEN LAKH THIRTY FIVE THOUSAND) FULLY PAID UP EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH AT A PRICE OF ₹ 1,850/- (RUPEES ONE THOUSAND EIGHT HUNDRED AND FIFTY ONLY) PER FULLY PAID UP EQUITY SHARE ON A PROPORTIONATE BASIS THROUGH THE TENDER OFFER PROCESS

1. DETAILS OF THE BUYBACK OFFER AND OFFER PRICE

1.1 Pursuant to the resolution passed by the Board of Directors of Ajanta Pharma Limited (the "Company") (the Board of Directors of the Company are hereinafter referred to as the "Board" or the "Board of Directors") on November 3, 2020 ("Board Meeting"), the Company hereby announces the buyback of fully paid-up equity shares of face value of ₹ 2 each ("Shares" or "Equity Shares") of the Company not exceeding 7,35,000 (Seven Lakh Thirty Five Thousand) Equity Shares from the equity shareholders/ beneficial owners of Equity Shares of the Company including the promoter and members of the promoter group (the "Equity Shareholders" / "Shareholders") as on Record Date (as defined hereinafter), on a proportionate basis, through "tender offer" process, in accordance with Article 18 of the Articles of Association of the Company, Section 68, 69 and 70, and other applicable provisions of Companies Act, 2013 including any statutory modification(s) or re-enactment thereof (the "Companies Act"), and applicable rules thereunder including the Companies (Share Capital and Debentures) Rules, 2014, as amended, the Buyback Regulations, at a price of ₹ 1,850/- (Rupees One Thousand Eight Hundred and Fifty only) per Equity Share ("Buyback Price" / "Buyback Offer Price") payable in cash, for an aggregate maximum consideration not exceeding ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only) (the "Buyback Offer Size") (the process being hereinafter referred as the "Buyback" / "Buyback Offer"). The Buyback Offer Size and the Buyback Offer Price do not include taxes payable under Income Tax Act, 1961 and any expenses incurred or to be incurred for the Buyback viz., brokerage, turnover charges, taxes such as securities transaction tax and goods and services tax (if any), stamp duty, advisors fees, printing and dispatch expenses and other incidental and related expenses and charges ("Transaction Costs"). The Buyback Offer Size represents 5.52% and 5.26% of the aggregate of the Company's paid-up capital and free reserves as per the audited financial statements of the Company as on March 31, 2020 on a standalone and consolidated basis, respectively.

1.2 The Buyback is in accordance with the provisions of Companies Act, Article 18 of the Articles of Association of the Company, and subject to the provisions of the Buyback Regulations, and such other approvals, permissions as may be required from time to time from BSE Limited (the "BSE") and the National Stock Exchange of India Limited (the "NSE") (BSE and NSE are hereinafter together referred to as the "Stock Exchanges") where the Equity Shares of the Company are listed and from any other statutory and/or regulatory authority, as may be required and which may be agreed to by the Board and/or any committee thereof. The Buyback would be undertaken in accordance with circular bearing number CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015 and circular no. CFD/DCR2/CIR/P/2016/131 dated December 08, 2016, issued by Securities and Exchange Board of India ("SEBI") (the "SEBI Circulars"), which prescribes mechanism for acquisition of shares through stock exchange. In this regard, the Company will request NSE to provide the acquisition window.

1.3 In accordance with the provisions of Companies Act and Buyback Regulations, the Buyback Offer Size of ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only), represents 5.52% and 5.26% of the aggregate of the fully paid-up equity share capital and free reserves as per the audited standalone and consolidated financial statements of the Company for the financial year ended March 31, 2020, respectively (the last audited financial statements available as on the date of the Board Meeting approving the Buyback) and is within the statutory limits of 10% of the aggregate of the fully paid-up equity share capital and free reserves as on March 31, 2020 under the Board of Directors approval route as per the provisions of the Companies Act. Further, under the Companies Act, the number of equity shares that can be bought back in any financial year cannot exceed 25% of the total paid-up equity share capital of a company in that financial year. Since the Company proposes to Buyback up to 7,35,000 (Seven Lakh Thirty Five Thousand) Equity Shares representing 0.84% of the total number of Equity Shares in the total paid-up share capital of the Company (calculated on the basis of the total paid-up share capital of the Company as on October 31, 2020), the same is within the aforesaid 25% limit.

1.4 The maximum amount required by the Company for the said Buyback aggregating to ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only), and is within permitted limits. The Company confirms that as required under Section 68(2)(d) of the Companies Act and Regulation 4(ii) of Buyback Regulations, the ratio of the aggregate of secured and unsecured debts owed by the Company shall not be more than twice the fully paid-up share capital and free reserves on both standalone and consolidated basis after the Buyback.

1.5 The Buyback shall be on a proportionate basis from all the Equity Shareholders of the Company through the "Tender Offer" route, as prescribed under Regulation 4(iv) of the Buyback Regulations. Please see paragraph 12 below for details regarding record date and share entitlement for tender in the Buyback.

1.6 A copy of this Public Announcement is available on the Company's website www.ajantapharma.com, and is expected to be available on the website of SEBI www.sebi.gov.in and on the website of Stock Exchanges i.e., www.bseindia.com and www.nseindia.com during the period of the Buyback.

2. NECESSITY FOR BUYBACK

The Buyback is the acquisition by a company of its own shares. Buyback is an efficient form of returning surplus cash, which are over and above its ordinary capital requirements and in excess of any current investment plans to the members holding equity shares of the company, in an expedient, efficient and cost effective manner. Additionally, the Company's management strives to increase the Equity Shareholders' value and the Buyback would result in following benefits, amongst other things:

- The Buyback would help in Improving Earnings Per Share (EPS), Return on Equity (ROE), Return on Capital Employed (ROCE);
- The Buyback will help in achieving optimal capital structure;
- The Buyback will help the Company to distribute surplus cash to the Equity Shareholders broadly in proportion to their shareholding, thereby, enhancing their overall return;
- The Buyback, which is being implemented through the tender offer route as prescribed under the Buyback Regulations, would involve allocation of number of shares as per the entitlement of the shareholders or 15% of the number of Equity Shares to be bought back whichever is higher, reserved for the small shareholders. The Company believes that this reservation for small shareholders would benefit a large number of public shareholders, who would get classified as "small shareholder" as per 2(i)(n) of the Buyback Regulations;
- The Buyback gives an option to Equity Shareholders to either (i) choose to participate and get cash in lieu of Equity Shares to be accepted under the Buyback offer or (ii) choose not to participate and enjoy a resultant increase in their percentage shareholding, post the Buyback offer, without any additional investment.

After considering the above mentioned factors and benefits to the Equity Shareholders, the Board decided to recommend Buyback of not exceeding 7,35,000 (Seven Lakh Thirty Five Thousand) Equity Shares (representing 0.84% of the total number of equity shares in the paid-up share capital of the Company) at a price of ₹ 1,850/- (Rupees One Thousand Eight Hundred and Fifty only) per Equity Share for an aggregate consideration of not exceeding ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only) excluding any taxes payable under Income Tax Act, 1961 and any expenses incurred or to be incurred for the Buyback, which represents 5.52% and 5.26% of the aggregate of the Company's paid-up capital and free reserves as per the audited financial statements of the Company as on March 31, 2020 on a standalone and consolidated basis, respectively.

3. MAXIMUM NUMBER OF SECURITIES THAT THE COMPANY PROPOSES TO BUYBACK

The Company is proposing to buyback up to 7,35,000 (Seven Lakh Thirty Five Thousand) fully paid-up equity shares of face value of ₹ 2 each representing 0.84% of the total number of Equity Shares in the total paid-up share capital of the Company (calculated on the basis of the total paid-up share capital of the Company as on October 31, 2020).

4. BUYBACK PRICE AND BASIS OF DETERMINING THE PRICE OF THE BUYBACK

4.1 The Buyback offer price of ₹ 1,850/- (Rupees One Thousand Eight Hundred and Fifty only) per Equity Share has arrived at after considering various factors such as the average closing prices of the Equity Shares on the Stock Exchanges where the Equity Shares of the Company are listed, the net-worth of the Company and the impact of the Buyback on the key financial ratios of the Company.

4.2 The Buyback Offer Price of ₹ 1,850/- (Rupees One Thousand Eight Hundred and Fifty only) per Equity Share represents: (i) premium of 16.80% on BSE and 16.72% on NSE over the volume weighted average price of the Equity Shares on BSE and NSE respectively for 3 months preceding the date of intimation to the BSE and NSE for the Board Meeting to consider the proposal of the Buyback; (ii) premium of 17.40% on BSE and 17.29% on NSE over the volume weighted average price of the Equity Shares on BSE and NSE respectively for 2 weeks preceding the date of intimation to the BSE and NSE for the Board Meeting to consider the proposal of the Buyback; (iii) premium of 16.39% on BSE and 18.23% on NSE over the closing market price of the Equity Shares on BSE and NSE as on the date of the intimation to BSE and NSE for the Board Meeting to consider the proposal of the Buyback.

5. MAXIMUM AMOUNT REQUIRED UNDER THE BUYBACK AND ITS PERCENTAGE OF THE TOTAL PAID-UP CAPITAL AND FREE RESERVES

5.1 The maximum amount required for Buyback will not exceed ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only) excluding Transaction Cost.

5.2 The maximum amount mentioned aforesaid represents 5.52% and 5.26% of the aggregate of the Company's paid-up capital and free reserves as per the audited financial statements of the Company as on March 31, 2020 on a standalone and consolidated basis, respectively.

5.3 The funds for the Buyback will be met out of internally generated cash resources of the Company or such other source as may be permitted by the Buyback Regulations or the Companies Act.

5.4 The funds borrowed, if any from banks and financial institutions will not be used for the Buyback.

6. METHOD TO BE ADOPTED FOR THE BUYBACK

The method to be adopted for the purpose of the Buyback shall be through the Tender Offer route as prescribed under the Buyback Regulations and circulars issued thereunder, including the "Mechanism for acquisition of shares through Stock Exchange" notified by the SEBI Circulars, or such other mechanism, for the Buy Back through Tender Offer route, as may be applicable. Please refer to Paragraph 12 below for details regarding the Record Date and shareholders entitlement for tender in the Buyback.

7. DETAILS OF PROMOTERS SHAREHOLDING AND OTHER DETAILS

7.1 The aggregate shareholding of the promoters and members of the promoter group (collectively referred to as the "Promoters and Promoter Group") and persons who are in control of the Company; directors of the promoter and member of promoter group, where such promoter or member of promoter group is a company; and the Directors and Key Managerial Personnel of the Company as on the date of the Board Meeting i.e. Tuesday, November 3, 2020 is given below:

i. Shareholding of the Promoters and Promoter Group and person in control of the Company:

Sr. No.	Name of shareholder	No. of Equity Shares held	No. of Equity Shares held in dematerialized form	Percentage (%) of issued Equity Share capital
1.	Yogesh Agrawal, trustee Yogesh Agrawal Trust	1,26,39,934	1,26,39,934	14.48
2.	Rajesh Agrawal, trustee Rajesh Agrawal Trust	1,26,39,933	1,26,39,933	14.48
3.	Aayush Agrawal, trustee Aayush Agrawal Trust	1,25,40,389	1,25,40,389	14.37
4.	Ravi Agrawal, trustee Ravi Agrawal Trust	1,25,45,180	1,25,45,180	14.38
5.	Gabs Investments Private Limited	83,92,282	83,92,282	9.62
6.	Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal	23,90,903	23,90,903	2.74
7.	Ravi Agrawal	1,90,000	1,90,000	0.22
8.	Mannalal Agrawal	1,70,000	1,70,000	0.19
9.	Aayush Agrawal	20,000	20,000	0.02
	Total	6,15,28,601	6,15,28,601	70.50

ii. Shareholding of directors of the Promoters and Promoter Group entity (i.e. Gabs Investment Private Limited ("GIPIL")) in the Company:

Sr. No.	Name	Designation in GIPIL	No. of Equity Shares held in the Company	Percentage (%) of issued Equity Share capital
1.	Yogesh Agrawal	Director	1,35,36,523 ⁽ⁱ⁾	15.51
2.	Rajesh Agrawal	Director	1,35,36,522 ⁽ⁱ⁾	15.51
3.	Ravi Agrawal	Director	1,33,32,906 ⁽ⁱ⁾	15.28
4.	Aayush Agrawal	Director	1,25,60,389 ⁽ⁱ⁾	14.39
	Total		5,29,66,340	60.69

(1): 1,26,39,934 Equity Shares held in capacity as trustee of Yogesh Agrawal Trust and 8,96,589 Equity Shares as partner of Ganga Exports, where the partner's share being 37.5%.

(2): 1,26,39,933 Equity Shares held in capacity as trustee of Rajesh Agrawal Trust and 8,96,589 Equity Shares as partner of Ganga Exports, where the partner's share being 37.5%.

(3): 1,25,45,180 Equity Shares held in capacity as trustee of Ravi Agrawal Trust, 1,90,000 Equity Shares held in individual name in the Company and 5,97,726 Equity Shares as partner of Ganga Exports, where the partners' share being 25.0%

(4): 1,25,40,389 Equity Shares held in capacity as trustee of Aayush Agrawal Trust and 20,000 Equity Shares held in individual name in the Company.

iii. Shareholding of the Directors and Key Managerial Personnel of the Company:

Sr. No.	Name	Designation	No. of Equity Shares held	Percentage (%) of issued Equity Share capital
1.	Yogesh Agrawal	Managing Director	1,35,36,523 ⁽ⁱ⁾	15.51
2.	Rajesh Agrawal	Joint Managing Director	1,35,36,522 ⁽ⁱ⁾	15.51
3.	Mannalal Agrawal	Chairman	1,70,000	0.19
4.	Arvind Agrawal	Chief Financial Officer	26,484	0.03
5.	Gaurang Shah	Company Secretary	1,000	Negligible
6.	Chandrakant Khetan	Independent Director	700	Negligible
	Total		2,72,71,229	31.25%

(1): 1,26,39,934 Equity Shares held in capacity as trustee of Yogesh Agrawal Trust and 8,96,589 Equity Shares as partner of Ganga Exports, where the partners' share being 37.5%.

(2): 1,26,39,933 Equity Shares held in capacity as trustee of Rajesh Agrawal Trust and 8,96,589 Equity Shares as partner of Ganga Exports, where the partners' share being 37.5%.

Apart from the above, none of the Directors or Key Managerial Personnel of the Company hold any Equity Shares in the Company.

7.2 No Equity Shares or other specified securities in the Company have been either purchased or sold (either through the Stock Exchanges or off market transactions) by Promoters and Promoter Group and persons who are in control of the Company; directors of the promoter and member of promoter group, where such promoter or member of promoter group is a company; and the Directors and Key Managerial Personnel of the Company during a period of six months preceding the date of the Board Meeting and from the date of Board Meeting till the date of Public Announcement, other than the following:

Aggregate number of Equity Shares purchased or (sold)	Nature of Transaction	Maximum Price (₹)	Date of Maximum Price	Minimum Price (₹)	Date of Minimum Price
Mannalal Agrawal					
1,70,000	Refer Note	Not Applicable	September 18, 2020	Not Applicable	September 18, 2020
Gaurang Shah					
100	Open market purchase	1,444.44	August 31, 2020	1,444.44	August 31, 2020

Note: Distribution of shares by the Mannalal Agrawal Trust to beneficiary of the Trust i.e. Mannalal Agrawal

7.3 Intention of Promoters and Promoter Group to participate in the Buyback:

In terms of the Buyback Regulations, under the Tender Offer route, the promoter and members of promoter group of the Company have an option to participate in the Buyback. In this regard, certain members of the Promoters and Promoter Group as listed in paragraph 7.1(i) above have expressed their intention, vide their letters, each dated November 3, 2020 to participate in the Buyback and tender up to an aggregate maximum number of 89,90,903 (Eighty Nine Lakh Ninety Thousand Nine Hundred Three) Equity Shares or such lower number of Equity Shares as required in compliance with Buyback Regulations.

Sr. No.	Name of shareholder	No. of Equity Shares held	Maximum number of Equity Shares intended to tender
1.	Yogesh Agrawal, trustee Yogesh Agrawal Trust	1,26,39,934	13,00,000
2.	Rajesh Agrawal, trustee Rajesh Agrawal Trust	1,26,39,933	13,00,000
3.	Aayush Agrawal, trustee Aayush Agrawal Trust	1,25,40,389	22,00,000
4.	Ravi Agrawal, trustee Ravi Agrawal Trust	1,25,45,180	18,00,000
5.	Gabs Investments Private Limited	83,92,282	NIL
6.	Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal	23,90,903	23,90,903
7.	Ravi Agrawal	1,90,000	NIL
8.	Mannalal Agrawal	1,70,000	NIL
9.	Aayush Agrawal	20,000	NIL
	Total	6,15,28,601	89,90,903

7.4 Since the entire shareholding of the Promoters and Promoter Group who intends to participate in the Buyback is in the demat mode, the details of the date and price of acquisition/ sale of entire Equity Shares that the participating Promoters and Promoter Group has acquired/sold till date as per the information provided by Promoters and Promoter Group, each vide their letter dated November 3, 2020, are set-out below:

Date of Transaction	No. of Equity Shares	Acquisition/ Sale Consideration	Nature of Transaction/Consideration
Yogesh Agrawal, trustee Yogesh Agrawal Trust			
March 23, 2017	1,27,49,999	Gift	Inter-se transfer of Equity Shares from Vimal Mannalal Agrawal
March 22, 2019	(1,10,065)	₹ 14.29 ⁽ⁱ⁾ crores	Tendered in buyback offer of the Company
Total	1,26,39,934		
Rajesh Agrawal, trustee Rajesh Agrawal Trust			
March 22, 2017	1,27,49,999	Gift	Inter-se transfer of Equity Shares from Mannalal Agrawal
March 22, 2019	(1,10,066)	₹ 14.29 ⁽ⁱ⁾ crores	Tendered in buyback offer of the Company
Total	1,26,39,933		
Aayush Agrawal, trustee Aayush Agrawal Trust			
March 27, 2017	1,26,60,000	Gift	Inter-se transfer of Equity Shares from Purushottam Agrawal
March 22, 2019	(1,19,611)	₹ 15.53 ⁽ⁱ⁾ crores	Tendered in buyback offer of the Company
Total	1,25,40,389		
Ravi Agrawal, trustee Ravi Agrawal Trust			
March 24, 2017	1,26,59,999	Gift	Inter-se transfer of Equity Shares from Madhusudan Agrawal
March 22, 2019	(1,14,819)	₹ 14.84 ⁽ⁱ⁾ crores	Tendered in buyback offer of the Company
Total	1,25,45,180		
Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal			
March 31, 2006	6,85,000	NIL	Inter-se transfer of Equity Shares from Vimal P. Agrawal, Samata P. Agrawal and Mamta P. Agrawal
August 10, 2012	13,70,000		Split of Equity Shares from face value of ₹10 to ₹5
September 19, 2013	6,85,000	NIL	Bonus issue of Equity Shares in the ratio of 1:2
March 23, 2015	51,37,500		Split of Equity Shares from face value of ₹5 to ₹2
July 10, 2017	(2,15,000)	₹ 33.33 crores	Market sale
July 11, 2017	(24,85,000)	₹ 372.77 crores	Market sale
March 22, 2019	(46,597)	₹ 6.05 ⁽ⁱ⁾ crores	Tendered in buyback offer of the Company
Total	23,90,903		

⁽ⁱ⁾Net of brokerage charges.

8. NO DEFAULTS

The Board confirms that the Company has not defaulted in the repayment of the deposits accepted either before or after the commencement of the Companies Act, interest payment thereon, redemption of debentures or preference shares or payment of dividend to any shareholder or repayment of any term loan or interest payable thereon to any financial institutions or banking company.

9. CONFIRMATION BY THE BOARD OF DIRECTORS

The Board has confirmed on the date of Board Meeting (i.e. Tuesday, November 3, 2020) that it has made a full enquiry into the affairs and prospects of the Company and has formed an opinion that:

- Immediately following the date of the Board Meeting, there will be no grounds on which the Company could be found to be unable to pay its debts;
- As regards the Company's prospects for the year immediately following date of the Board Meeting and having regard to the Board's intentions with respect to the management of the Company's business during that year and to the amount and character of the financial resources which will in the Board's view be available to the Company during that year, the Company will be able to meet its liabilities as and when they fall due and will not be rendered insolvent within a period of one year from that date of Board Meeting; and
- In forming the opinion, the Board has taken into account the liabilities as if the Company were being wound up under the provisions of the Companies Act 1956 or Companies Act 2013 and Insolvency and Bankruptcy Code 2016, as the case may be (including prospective and contingent liabilities).

10. REPORT BY THE COMPANY'S STATUTORY AUDITOR

The text of the report dated November 3, 2020 received from B S R & Co. LLP, Chartered Accountants, the statutory auditor of the Company, addressed to the Board of Directors of the Company is reproduced below:

Quote

"The Board of Directors
The Ajanta Pharma Limited
Ajanta House, 98 Govt Industrial Area, Kandivli (W)
MUMBAI 400 067
3 November 2020
Dear Sirs

Independent Auditors' Report in respect of proposed buy-back of equity shares by Ajanta Pharma Limited in terms of clause (xi) of Schedule I of Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended

- This report is issued in accordance with the terms of our engagement letter dated 9 July 2018 and addendum to engagement letter dated 25 October 2020 with Ajanta Pharma Limited ("the Company").
- The Board of Directors of the Company have approved a proposed buy-back of equity shares by the Company at its meeting held on 3 November 2020, in pursuance of the provisions of Section 68, 69 and 70 of the Companies Act, 2013 ("the Act") read with the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended ("SEBI Buy-back Regulations"). The accompanying Statement of permissible capital payment (including premium) (Annexure A) as at 31 March 2020 (hereinafter referred as the "Statement") is prepared by the management of the Company, which we have initiated for identification purpose only.

Management's Responsibility for the Statement

- The preparation of the Statement in accordance with Section 68(2) of the Act and in compliance with Section 68, 69 and 70 of the Act and SEBI Buy-back Regulations, is the responsibility of the Management of the Company, including the computation of the amount of the permissible capital payment, the preparation and maintenance of all accounting and other relevant supporting records and documents. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the Statement and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.

Auditors' Responsibility

- Pursuant to the requirements of the SEBI Buy-back Regulations, it is our responsibility to provide reasonable assurance whether:
 - we have inquired into the state of affairs of the Company in relation to its latest audited standalone and audited consolidated financial statements as at and for the year ended 31 March 2020;

- the amount of permissible capital payment (including premium) as stated in Annexure A for the proposed buy-back of equity shares has been properly determined considering the audited standalone financial statements and audited consolidated financial statements in accordance with Section 68(2) of the Act; and
- the Board of Directors of the Company in their meeting dated 3 November 2020, have formed the opinion as specified in clause (x) of Schedule I to the SEBI Buy-back Regulations on reasonable grounds and that the Company will not, having regard to its state of affairs, be rendered insolvent within a period of one year from that date.

Auditors' Responsibility (Continued)

- The audited standalone financial statements and audited consolidated financial statements referred to in paragraph 5 above, which we have considered for the purpose of this report, have been audited by us, on which we have issued an unmodified audit opinion vide our reports dated 20 May 2020.
- Our engagement involves performing procedures to obtain sufficient appropriate evidence on the above reporting. The procedures selected depend on the auditor's judgement, including the assessment of the risks associated with the above reporting. We accordingly performed the following procedures:
 - Examined that the amount of permissible capital payment (including premium) for the buy-back as detailed in Annexure A is in accordance with the provisions of Section 68(2) of the Act;
 - Inquired into the state of affairs of the Company with reference to the audited standalone financial statements and audited consolidated financial statements as at and for the period ended 31 March 2020;
 - Traced the amounts of paid-up equity share capital, retained earnings and general Reserves as mentioned in Annexure A from the audited standalone financial statements and audited consolidated financial statements as at and for the year ended 31 March 2020;
 - Verified the arithmetical accuracy of the amounts mentioned in Annexure A; and
 - We have obtained appropriate representations from the Management of the Company.
- We conducted our examination of the Statement in accordance with the Guidance Note on Reports or Certificates for Special Purposes' (Revised 2016) issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.
- We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements.
- We have no responsibility to update this report for events and circumstances occurring after the date of this report.

Opinion

- Based on inquiries conducted and our examination as above, we report that:
 - We have inquired into the state of affairs of the Company in relation to its audited standalone financial statements and audited consolidated financial statements as at and for the year ended 31 March 2020;
 - The amount of permissible capital payment towards the proposed buy-back of equity shares as computed in the Statement attached herewith is, in our view properly determined in accordance with Section 68(2) of the Act. The amounts of share capital and free reserves have been extracted from the audited standalone financial statements and audited consolidated financial statements of the Company as at and for the year ended 31 March 2020; and

Opinion (Continued)

- The Board of Directors of the Company, in their meeting held on 3 November 2020 have formed their opinion as specified in clause (x) of Schedule I to the SEBI Buy-back Regulations, on reasonable grounds and that the Company, having regard to its state of affairs, will not be rendered insolvent within a period of one year from the date of passing the Board meeting resolution dated 3 November 2020.
- Based on the representations made by the management, and other information and explanations given to us, which to the best of our knowledge and belief were necessary for this purpose, we are not aware of anything to indicate that the opinion

favour of the Company, (iv) self-attested copy of PAN Card(s) of all Equity Shareholders, (v) any other relevant documents such as power of attorney, corporate authorization (including board resolution/specimen signature), notarized copy of death certificate and succession certificate or probated will, if the original Shareholder is deceased, etc., as applicable. In addition, if the address of the Equity Shareholder has undergone a change from the address registered in the Register of Members of the Company, the Equity Shareholder would be required to submit a self-attested copy of address proof consisting of any one of the following documents: valid Aadhar card, voter identity card or passport.

b. Based on these documents, the concerned Shareholder Broker shall place an order/bid on behalf of the Equity Shareholders holding Physical Shares who wish to tender Equity Shares in the Buyback, using the acquisition window of NSE. Upon placing the bid, the Shareholder Broker shall provide a TRS generated by the exchange bidding system to the Equity Shareholder. TRS will contain the details of order submitted like folio no., certificate no., distinctive no., no. of Equity Shares tendered etc.

c. Any Shareholder Broker/Equity Shareholder who places a bid for physical Equity Shares, is required to deliver the original share certificate(s) & documents (as mentioned above) along with TRS generated by exchange bidding system upon placing of bid, either by registered post, speed post or courier or hand delivery to the Registrar to the Buyback Offer i.e. Link Intime India Private Limited (at the address mentioned at paragraph 14 below) not later than 2 (two) days from the offer closing date. The envelope should be super scribed as **'Ajanta Pharma Limited - Buyback Offer 2020'**. One copy of the TRS will be retained by Registrar to the Buyback offer and it will provide acknowledgement of the same to the Shareholder Broker.

d. Equity Shareholders holding physical Equity Shares should note that physical Equity Shares will not be accepted unless the complete set of documents is submitted. Acceptance of the physical Equity Shares for Buyback by the Company shall be subject to verification as per the Buyback Regulations and any further directions issued in this regard. The Registrar to the Buyback Offer will verify such bids based on the documents submitted on a daily basis and till such verification, NSE shall display such bids as 'unconfirmed physical bids'. Once Registrar to the Buyback Offer confirms the bids, they will be treated as 'confirmed bids'.

11.11 METHOD OF SETTLEMENT

Upon finalization of the basis of acceptance as per Buyback Regulations:

a. The Company will pay consideration to Company's Broker who will transfer the funds pertaining to the Buyback to the Clearing Corporation's bank account as per the prescribed schedule. For Equity Shares accepted under the Buyback, the Equity Shareholders will receive funds pay-out in their bank account from the Clearing Corporation.

b. The Demat Shares bought back would be transferred directly to the demat account of the Company opened for the Buyback (the **"Company Demat Account"**) provided it is indicated by the Company's Broker or it will be transferred by the Company's Broker to the Company Demat account on receipt of the Equity Shares from the clearing and settlement mechanism of the NSE.

c. The eligible Equity Shareholders will have to ensure that they keep the depository participant ("DP") account active and unblocked to receive credit in case of return of Demat Shares, due to rejection or due to non-acceptance in the Buyback.

d. Excess Demat Shares or unaccepted Demat Shares, if any, tendered by the eligible Equity Shareholders would be returned to them by the Clearing Corporation. Any excess Physical Shares pursuant to proportionate acceptance/ rejection will be returned back to the concerned Eligible Shareholders directly by the Registrar to the Buyback. The Company is authorized to split the share certificate and issue new consolidated share certificate for the unaccepted Physical Shares, in case the Physical Shares accepted by the Company are less than the Physical Shares tendered in the Buyback.

e. The settlement of fund obligation for Demat and Physical Shares shall be effected as per the SEBI Circulars and as prescribed by NSE and Clearing Corporation from time to time. For Demat Shares accepted under the Buyback, such beneficial owners will receive funds payout in their bank account as provided by the depository system directly to the Clearing Corporation and in case of Physical Shares, the Clearing Corporation will release the funds to the Shareholder Broker(s) as per secondary market payout mechanism. If such shareholder's bank account details are not available or if the funds transfer instruction is rejected by the Reserve Bank of India ("RBI")/ bank(s), due to any reasons, then the amount payable to the concerned shareholders will be transferred to the Shareholder Broker for onward transfer to such shareholders.

f. In case of certain shareholders viz., NRIs, non-residents etc. (where there are specific regulatory requirements pertaining to funds payout including those prescribed by the RBI) who do not opt to settle through custodians,

the funds payout would be given to their respective Shareholder Broker's settlement accounts for releasing the same to such shareholder's account.

g. The Shareholder Broker would issue contract note to the Eligible Shareholders tendering Equity Shares in the Buyback. The Company's Broker would also issue a contract note to the Company for the Equity Shares accepted under the Buyback.

h. Equity Shareholders who intend to participate in the Buyback should consult their respective Shareholder Broker for payment of any cost, charges and expenses (including brokerages that may be levied by the Shareholder Broker upon the selling Equity Shareholders for tendering Equity Shares in the Buyback (secondary market transaction)). The Company accepts no responsibility to bear or pay such additional cost, charges and expenses (including brokerage) incurred solely by the selling Equity Shareholders.

i. The Equity Shares bought back will be extinguished in the manner and following the procedure prescribed in the Buyback Regulations.

12. RECORD DATE AND SHAREHOLDER ENTITLEMENT

12.1 As required under the Buyback Regulations, the Company has fixed Friday, November 13, 2020 as the record date (the **"Record Date"**) for the purpose of determining the entitlement and the names of the shareholders, who are eligible to participate in the Buyback.

12.2 The Equity Shares proposed to be bought back by the Company, as part of this Buyback Offer shall be divided in to two categories: (a) reserved category for Small Shareholders (A **"Small Shareholder"** is defined in the Buyback Regulations as a shareholder, who holds equity shares or other specified securities whose market value, on the basis of closing price of the Equity Shares on the recognized stock exchange registering the highest trading volume in respect of such shares, as on record date, is not more than ₹ 2,00,000 (Rupees Two Lakh Only); and (b) the general category for all other shareholders.

12.3 In accordance with Regulation 6 of the Buyback Regulations, 15% (fifteen per cent) of the number of Equity Shares which the Company proposes to Buyback, or number of Equity Shares entitled as per shareholding of Small Shareholders, whichever is higher, shall be reserved for the Small Shareholders as part of this Buyback.

12.4 Based on shareholding as on the Record Date, the Company will determine the entitlement of each shareholder to tender their Equity Shares in the Buyback. This entitlement for each shareholder will be calculated based on the number of Equity Shares held by the respective shareholder as on the Record Date and the ratio of Buyback applicable in the category to which such shareholder belongs.

12.5 In order to ensure that the same eligible Equity Shareholders with multiple demat accounts/ folios do not receive a higher entitlement under the Small Shareholder category, the Company will club together the Equity Shares held by such shareholders with a common PAN for determining the category (Small Shareholder or General Category) and the Buyback Entitlement. In case of joint shareholding, the Company will club together the Equity Shares held in cases where the sequence of the PANs of the joint shareholders is identical. In case of shareholders holding Physical Shares, where the sequence of PANs is identical and where the PANs of all joint shareholders are not available, the Company will check the sequence of the names of the joint holders and club together the Equity Shares held in such cases where the sequence of the PANs and name of joint shareholders are identical. The shareholding of institutional investors like mutual funds, pension funds/ trusts, insurance companies, foreign institutional investors/ foreign portfolio investors etc., with common PAN are not proposed to be clubbed together for determining their entitlement and will be considered separately, where these Equity Shares are held for different schemes/sub-accounts and have a different demat account nomenclature based on information prepared by the Registrar to the Buyback as per the shareholder records received from the Depositories. Further, the Equity Shares held under the category of "dearing members" or "corporate body margin account" or "corporate body – broker" as per the beneficial position data as on Record Date with common PAN are not proposed to be clubbed together for determining their entitlement and will be considered separately, where these Equity Shares are assumed to be held on behalf of clients.

12.6 The eligible Equity Shareholders' participation in the Buyback will be voluntary. The Equity Shareholders can choose to participate and get cash in lieu of Equity Shares to be accepted under the Buyback or they may choose to not participate and enjoy a resultant increase in their percentage shareholding, post Buyback, without additional investment. The eligible Equity Shareholders may also accept a part of their entitlement. The Equity Shareholders also have the option of tendering additional shares (over and above their entitlement) and participate in the shortfall created due to non-participation of some other Equity Shareholders, if at all.

12.7 The maximum tender under the Buyback by any shareholder cannot exceed the number of Equity Shares held by the shareholder as on the Record Date.

12.8 The Equity Shares tendered as per the entitlement by shareholders as well as additional shares tendered, if any, will be accepted as per the procedure laid down in Buyback Regulations.

12.9 Detailed instructions for participation in the Buyback (tendering of Equity Shares in the Buyback) as well as the relevant time table will be included in the Letter of Offer which will be sent in due course to the Equity Shareholders as on Record Date and the Company shall comply with the SEBI circular Nos. SEBI/CIR/CFD/DCR1/CIR/P/2020/83 dated May 14, 2020 and SEBI/HO/CFD/DCR2/CIR/P/2020/139 dated July 27, 2020 on "Relaxations relating to procedural matters – Takeovers and Buy-back".

13. COMPLIANCE OFFICER

The Company has designated Mr. Gaurang Shah as the compliance officer for the purpose of the Buyback.

Mr. Gaurang Shah, Company Secretary
Ajanta Pharma Limited
'Ajanta House', 98 Govt Industrial Area, Charkop, Kandivli (West), Mumbai - 400 067, Maharashtra, India
Tel: 022 6806 1000; Fax: 022 6806 1200;
Email: gaurang.shah@ajantapharma.com; **Website:** www.ajantapharma.com

Investor may contact the Compliance Officer for any clarification or to address their grievances, if any, during office hours i.e. 10:00 a.m. IST to 5:00 p.m. IST on all working days except Saturday, Sunday and public holidays.

14. INVESTOR SERVICE CENTRE AND REGISTRAR TO THE BUYBACK OFFER

In case of any query, the shareholders may contact the Registrar to the Buyback on any day except Saturday, Sunday and public holiday from 10:00 a.m. IST to 5:00 p.m. IST i.e., at the following address:

LINKIntime

LINK INTIME INDIA PRIVATE LIMITED
C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India
Tel: +91 22 4918 6200; Fax: +91 22 4918 6195;
E-mail: ajantapharma.buyback2020@linkintime.co.in;
Website: www.linkintime.co.in;
Contact Person: Mr. Sumet Deshpande
SEBI Registration Number: INR000004058; **Validity Period:** Permanent
Corporate Identity Number: U67190MH1999PTC118368

15. MANAGER TO THE BUYBACK OFFER

IndusInd Bank

INDUSIND BANK LIMITED
11th Floor, One Indiabulls Centre, Tower 1, 841 Senapati Bapat Marg, Elphinstone Road, Mumbai – 400 013, Maharashtra, India
Tel.: +91 (22) 7143 2206; Fax: +91 (22) 7143 2270;
Email: apl.buyback@indusind.com; **Website:** www.indusind.com
Contact Person: Mr. Priyanka Shetty/ Ms. Nikita Somani
SEBI Registration Number: INM000005031; **Validity Period:** Permanent
Corporate Identity Number: L65191PN1999PLC076333

16. DIRECTORS' RESPONSIBILITY

As per Regulation 24(i)(a) of the Buyback Regulations, the Board of Directors of the Company accept full and final responsibility for the information contained in this Public Announcement or any other information, advertisements, circulars, brochures, publicity materials etc. which may be issued in relation to the Buyback and confirms that the information in such document contains true, factual and material information and does not contain any misleading information.

For and on behalf of the Board of Directors of Ajanta Pharma Limited

Sd/-	Sd/-	Sd/-
Yogesh Agrawal Managing Director (DIN: 00073673)	Rajesh Agrawal Joint Managing Director (DIN: 00302467)	Gaurang Shah Company Secretary
Place : Mumbai Date : November 4, 2020		



GSE Limited
CIN : L99999MH1980PLC011879
Registered Office : Plot No E-1, Road No. 7,
Wagle Industrial Estate, Thane-400604
Website : www.geelimited.com **Email :** Shares@geelimited.com
Telephone : +91 22 25820619, **Fax:** 02522-281199

NOTICE is hereby given that pursuant to Regulation 47 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the Meeting of the Board of Directors of the Company will be held on Tuesday, November 10, 2020, inter alia to consider and approve the Un-audited Financial Results of the Company for the quarter ended September 30, 2020.

This notice is also available on Company's website www.geelimited.com and on the website of stock exchange www.bseindia.com.

By order of the Board
For GEE Limited
sd/-
Shivani Sharma
Company Secretary and Compliance Officer

Date : November 4, 2020

RISHI LASER LIMITED
CIN: L39999MH1992PLC066412
612, V. K. Indl. Estate, 10/14,
Pais Street, Byculla (W) Mumbai 400 011
Email : rli.mumbai@rishilaser.com
Web : www.rishilaser.com

NOTICE

Notice is hereby given that pursuant to Regulation 47 read with Regulation 29 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and any amendments thereof, a meeting of the Board of Directors of the Company will be held on Wednesday, November 11, 2020, inter alia, to consider, approve and take on record the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2020.

The said notice can be accessed on the Company's website at www.rishilaser.com and also on the website of the Stock Exchange at www.bseindia.com

For RISHI LASER LIMITED
Harshad Patel
Managing Director

Place : Mumbai
Date : November 5, 2020

ABC INDIA LIMITED
CIN: L63011WB1972PLC217415
Regd. Office: P-10, New C.I.T. Road,
Kolkata – 700 073
Corporate Office: 40/8, Ballygunge Circular
Road, Kolkata – 700 019
Phone: (033) 22371745, 24614156,
Fax: (033) 24614193
Email: vrm.d@abcindia.com
Website: www.abcindia.com

NOTICE

NOTICE is hereby given that pursuant to Regulations 29(1)(a) and 47(1)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, a Meeting of the Board of Directors of the Company will be held at the Corporate Office of the Company at 40/8, Ballygunge Circular Road, Kolkata - 700019 on Thursday, 12th November, 2020 at 03:00 P.M. inter alia, to consider and approve the Un-audited Financial Results for the quarter & half year ended 30th September, 2020. This information is also available at the website of the Company at www.abcindia.com and website of the Stock Exchanges at www.bseindia.com and www.cse-india.com.

By Order of the Board
For ABC INDIA LIMITED
sd/-
Sanjay Agarwal
Company Secretary

Place : Kolkata
Date : 04.11.2020

ELNET TECHNOLOGIES LIMITED
Regd. Office: TS 140, Block No.2 & 9,
Rajiv Gandhi Salai, Taramani, Chennai - 600 113.
Ph: 044-2254-1061/1137, Fax: 044-2254-1955
Email: elnetcity@gmail.com
Website: www.elnettechnologies.com
CIN : L72300TN1999PLC019459

NOTICE

NOTICE is hereby given that pursuant to Regulation 47 read with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the 17th Meeting of Board of Directors of ELNET TECHNOLOGIES LIMITED is scheduled to be held on Wednesday, the 11th day of November, 2020 inter alia to consider and approve the Unaudited financial results for the quarter and half year ended 30th Sep, 2020.

The above information can be viewed on the website of the Company at www.elnettechnologies.com and website of the stock exchange where the shares of the Company is listed i.e., www.bseindia.com.

For Elnet Technologies Limited
Sd/-
T. Joswa Johnson
Company Secretary

Date : 4th November, 2020
Place : Chennai

पंजाब नैशनाल बैंक  **punjab national bank**
... करोसे का प्रतीक ...the name you can BANK upon!

Information Technology Division,
HO, 5, Sansad Marg, New Delhi-110 001
(Email Id: itdhw@pnb.co.in, Phone : 011-23311452)

TENDER NOTICE

Punjab National Bank invites online bids (both technical and commercial) from eligible bidders for **RFP for Supply, Installation, Implementation and Maintenance of Software Defined – Wide Area Network (SD-WAN) Solution.**

Interested bidders may visit our e-Procurement website <https://etender.pnbnet.in> or <https://www.pnbindia.in> for downloading the detailed RFP document. The Bids are required to be submitted online using digital certificates (Signing & encryption) through our e-Procurement system. Last date for online bid preparation and bid submission is **25.11.2020 at 1600 hrs.** and bid submission is **26.11.2020 at 1400 hrs.**

All future communications related to RFP will be uploaded on our websites <https://etender.pnbnet.in> and <https://www.pnbindia.in>.

Asst. General Manager

NOTICE

 **SBI MUTUAL FUND**
A PARTNER FOR LIFE

NOTICE CUM ADDENDUM TO THE SCHEME INFORMATION DOCUMENT / KEY INFORMATION MEMORANDUM OF SBI MULTI ASSET ALLOCATION FUND

Notice is hereby given that SBI Mutual Fund Trustee Company Private Limited, Trustees of SBI Mutual Fund have approved the following change in the benchmark index of SBI Multi Asset Allocation Fund (the Scheme), an open ended scheme investing in equity, debt, and gold & gold related instruments including ETFs and such other asset classes as SEBI may prescribe from time to time, with effect from **November 06, 2020:**

Existing Benchmark Index	Revised Benchmark Index
1/3 NIFTY + 1/3 CRISIL Composite Bond Fund Index + 1/3 Price of Gold	45% CRISIL 10 year Gilt Index + 40% NIFTY 50 TRI + 15% Price of Gold

The composition of the revised benchmark index will be more representative and reflective in benchmarking the performance of the Scheme.

All other terms and conditions of the Scheme remains unchanged. This addendum forms an integral part of the Scheme Information Document / Key Information Memorandum of the Scheme as amended from time to time.

Investors are requested to kindly take note of the above.

For SBI Funds Management Private Limited
Sd/-
Vinay M. Tonse
Managing Director & CEO

Place: Mumbai
Date: November 04, 2020

Asset Management Company: SBI Funds Management Private Limited (A Joint Venture between SBI & AMUNDI) (CIN: U65990MH1992PTC0685289) **Trustee:** SBI Mutual Fund Trustee Company Pvt. Ltd. (CIN: U65991MH2003PTC138496) **Sponsor:** State Bank of India **Regd Office:** 9th Floor, Crescenzo, C – 38 & 39, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai – 400051
Tel: 91-22-61793000 • **Fax:** 91-22-67425687 • **E-mail:** partnerforlife@sbfm.com • www.sbfm.com

Mutual Fund investments are subject to market risks, read all scheme related documents carefully. SBIMF/2020/NOV/01

PTL Enterprises Limited
Regd. Office: 3rd Floor, Areekal Mansion, Near Manorama Junction, Panampilly Nagar, Kochi- 682036
CIN: L25111KL1959PLC009300
Website: www.ptlenterprise.com, **Email:** investors@ptlenterprise.com
Tel: 0484-4012046, 4012047, **Fax:** (0484) - 4012048

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020

SL. No.	PARTICULARS	QUARTER ENDED		HALF YEAR ENDED	YEAR ENDED
		30.09.2020	30.09.2019	30.09.2020	31.03.2020
		(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(AUDITED)
1	Total income from operations	1,581.20	1,581.20	3,161.52	6,323.03
2	Net profit for the period (before tax & exceptional items)	1,271.03	1,484.32	3,128.83	5,800.55
3	Net profit for the period before tax (after exceptional items)	1,271.03	1,484.32	6,064.47	5,800.55
4	Net profit for the period after tax (after exceptional items)	906.42	1,192.45	5,219.01	4,393.57
5	Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	2,562.99	635.44	7,862.53	(87.73)
6	Paid-up equity share capital (equity shares of ₹ 2 each)	1,323.77	1,323.77	1,323.77	1,323.77
7	Reserves excluding revaluation reserves				13,919.28
8	Earnings per share (of ₹ 2 each) (not annualised)				
	Basic (₹)	1.37	1.80	7.89	6.64
	Diluted (₹)	1.37	1.80	7.89	6.64

The above is an extract of the detailed format of quarter ended September 30, 2020 financial results filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The full format of the quarter ended September 30, 2020 financial results are available on the stock exchange websites (National Stock Exchange of India Limited (www.nseindia.com)) & BSE Limited (www.bseindia.com)) and on the Company's website (www.ptlenterprise.com).

For and on behalf of the Board of Directors of PTL ENTERPRISES LTD.

Sd/-
ONKAR S. KANWAR
Chairman

Place : New Delhi
Date : November 4, 2020

 **GARWARE**
TECHNICAL FIBRES

GARWARE TECHNICAL FIBRES LIMITED
(Formerly Garware-Wall Ropes Limited)

EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2020

Sr No	Particulars	Standalone				Consolidated			
		Quarter Ended	Half Year Ended	Quarter Ended	Year Ended	Quarter Ended	Half Year Ended	Quarter Ended	Year Ended
		30.09.2020 (Unaudited)	30.09.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)	30.09.2020 (Unaudited)	30.09.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)
1	Total income from operations (net)	28,709.19	44,969.71	24,223.90	101,385.25	27,656.84	44,046.90	24,223.90	98,527.43
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	5,857.30	8,131.52	4,354.38	21,620.19	5,768.63	8,025.09	4,352.39	17,886.30
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	5,857.30	8,131.52	4,354.38	21,620.19	5,768.63	8,025.09	4,352.39	17,886.30
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	4,551.75	6,351.56	4,626.25	17,800.01	4,434.65	6,202.65	4,624.24	14,053.02
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and other Comprehensive Income (after tax)]	4,625.46	6,475.09	4,616.78	17,209.28	4,508.33	6,326.17	4,614.77	13,462.28
6	Equity Share Capital (Face Value is ₹ 10/- per share)	2,093.56	2,093.56	2,188.21	2,188.21	2,093.56	2,093.56	2,188.21	2,188.21
7	Reserves (excluding Revaluation Reserve)				75,104.15				71,723.95
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations)								
	(a) Basic EPS:	21.09	29.42	21.13	81.35	20.54	28.73	21.13	64.22
	(b) Diluted EPS:	21.09	29.42	21.13	81.35	20.54	28.73	21.13	64.22

Notes:

1. The above is an extract of the detailed format of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended on 30th September, 2020, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended on 30th September, 2020 is available on the Company's website at www.garwarefibres.com and also on the Stock Exchanges websites, i.e., on BSE Limited at www.bseindia.com and on The National Stock Exchange of India Limited at www.nseindia.com.

2. The Unaudited Standalone Financial Results of Garware Technical Fibres Limited ("the Company") as well as Consolidated Financial Results of the Company and its Subsidiaries and its associates for the quarter and half year ended 30th September, 2020 ("the Financial Statements"), were reviewed by the Audit Committee and have been taken on record and approved by the Board of Directors at its meeting held on Wednesday, 04th November, 2020. The Statutory Auditors of the Company have carried out a "Limited Review" of the Financial Statements for the quarter and half year ended 30th September, 2020.

3. The Members of the Company vide Special Resolution passed on 10th February, 2019 have approved reduction of capital of the Company, which comprises of cancellation of 9,46,500 equity shares of ₹ 10/- each, held by GWRL Managerial Staff Welfare Trust ("the Trust") and adjustment of outstanding advance payable by the Trust against Securities (Share) Premium Account. Hon'ble National Company Law Tribunal, Mumbai Bench has vide its Order dated 13th February, 2020 (the certified copy of the same was received on 15th July, 2020) allowed the Company's application and confirmed the said special resolution passed by the shareholders ("NCLT Order"). The Registrar of Companies, Pune has registered the said NCLT Order vide its certificate dated 5th August, 2020. The Company has given effect to the said reduction of capital by cancelling the shares held by the Trust and by adjustment in its Security Premium Account on 26th August, 2020.

For Garware Technical Fibres Limited
Sd/-
V. R. GARWARE
Chairman & Managing Director
DIN: 00092201

Place : Pune
Date : 04th November, 2020

Regd. Off: Plot No. 11, Block D-1, M.I.D.C., Chinchwad, Pune - 411 019.
CIN: L25209MH1978PLC018939; Telephone No.: (+91-20) 27990000; E-mail: pune_admin@garwarefibres.com; Website: www.garwarefibres.com

Better Ideas In Action



AJANTA PHARMA LIMITED

CIN : L24230MH1979PLC022059

Registered & Corporate Office: 'Ajanta House', 98 Govt Industrial Area, Charkop, Kandivli (West), Mumbai - 400 067, Maharashtra, India
Tel.: +91 22 6606 1000. **Fax:** +91 22 6606 1200 | **E-mail:** investorgrievance@ajantapharma.com
Website: www.ajantapharma.com

PUBLIC ANNOUNCEMENT FOR THE ATTENTION OF EQUITY SHAREHOLDERS/ BENEFICIAL OWNERS OF EQUITY SHARES OF AJANTA PHARMA LIMITED FOR BUYBACK OF EQUITY SHARES THROUGH TENDER OFFER UNDER THE SECURITIES AND EXCHANGE BOARD OF INDIA (BUY-BACK OF SECURITIES), REGULATIONS, 2018, AS AMENDED.

This Public Announcement (the "Public Announcement") is being made in relation to the Buyback (as defined hereinafter) pursuant to the provisions of Regulation 7(i) and other applicable provisions of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended (the "Buyback Regulations") for the time being in force including any statutory modifications and amendments from time to time and contains the disclosures as specified in Schedule II to the Buyback Regulations read with Schedule I of the Buyback Regulations.

CASH OFFER FOR BUYBACK OF NOT EXCEEDING 7,35,000 (SEVEN LAKH THIRTY FIVE THOUSAND) FULLY PAID UP EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH AT A PRICE OF ₹ 1,850/- (RUPEES ONE THOUSAND EIGHT HUNDRED AND FIFTY ONLY) PER FULLY PAID UP EQUITY SHARE ON A PROPORTIONATE BASIS THROUGH THE TENDER OFFER PROCESS

1. DETAILS OF THE BUYBACK OFFER AND OFFER PRICE

1.1 Pursuant to the resolution passed by the Board of Directors of Ajanta Pharma Limited (the "Company") (the Board of Directors of the Company are hereinafter referred to as the "Board" or the "Board of Directors") on November 3, 2020 ("Board Meeting"), the Company hereby announces the buyback of fully paid-up equity shares of face value of ₹ 2 each ("Shares" or "Equity Shares") of the Company not exceeding 7,35,000 (Seven Lakh Thirty Five Thousand) Equity Shares from the equity shareholders/ beneficial owners of Equity Shares of the Company including the promoter and members of the promoter group (the "Equity Shareholders" / "Shareholders") as on Record Date (as defined hereinafter), on a proportionate basis, through "tender offer" process, in accordance with Article 18 of the Articles of Association of the Company, Section 68, 69 and 70, and other applicable provisions of Companies Act, 2013 including any statutory modification(s) or re-enactment thereof (the "Companies Act"), and applicable rules thereunder including the Companies (Share Capital and Debentures) Rules, 2014, as amended, the Buyback Regulations, at a price of ₹ 1,850/- (Rupees One Thousand Eight Hundred and Fifty only) per Equity Share ("Buyback Price" / "Buyback Offer Price") payable in cash, for an aggregate maximum consideration not exceeding ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only) (the "Buyback Offer Size") (the process being hereinafter referred as the "Buyback" / "Buyback Offer"). The Buyback Offer Size and the Buyback Offer Price do not include taxes payable under Income Tax Act, 1961 and any expenses incurred or to be incurred for the Buyback viz., brokerage, turnover charges, taxes such as securities transaction tax and goods and services tax (if any), stamp duty, advisors fees, printing and dispatch expenses and other incidental and related expenses and charges ("Transaction Costs"). The Buyback Offer Size represents 5.52% and 5.26% of the aggregate of the Company's paid-up capital and free reserves as per the audited financial statements of the Company as on March 31, 2020 on a standalone and consolidated basis, respectively.

1.2 The Buyback is in accordance with the provisions of Companies Act, Article 18 of the Articles of Association of the Company, and subject to the provisions of the Buyback Regulations, and such other approvals, permissions as may be required from time to time from BSE Limited (the "BSE") and the National Stock Exchange of India Limited (the "NSE") (BSE and NSE are hereinafter together referred to as the "Stock Exchanges") where the Equity Shares of the Company are listed and from any other statutory and/or regulatory authority, as may be required and which may be agreed to by the Board and/or any committee thereof. The Buyback would be undertaken in accordance with circular bearing number CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015 and circular no. CFD/DCR2/CIR/P/2016/131 dated December 09, 2016, issued by Securities and Exchange Board of India ("SEBI") (the "SEBI Circulars"), which prescribes mechanism for acquisition of shares through stock exchange. In this regard, the Company will request NSE to provide the acquisition window.

1.3 In accordance with the provisions of Companies Act and Buyback Regulations, the Buyback Offer Size of ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only), represents 5.52% and 5.26% of the aggregate of the fully paid-up equity share capital and free reserves as per the audited standalone and consolidated financial statements of the Company for the financial year ended March 31, 2020, respectively (the last audited financial statements available as on the date of the Board Meeting approving the Buyback) and is within the statutory limits of 10% of the aggregate of the fully paid-up equity share capital and free reserves as on March 31, 2020 under the Board of Directors approval route as per the provisions of the Companies Act. Further, under the Companies Act, the number of equity shares that can be bought back in any financial year cannot exceed 25% of the total paid-up equity share capital of a company in that financial year. Since the Company proposes to Buyback up to 7,35,000 (Seven Lakh Thirty Five Thousand) Equity Shares representing 0.84% of the total number of Equity Shares in the total paid-up share capital of the Company (calculated on the basis of the total paid-up share capital of the Company as on October 31, 2020), the same is within the aforesaid 25% limit.

1.4 The maximum amount required by the Company for the said Buyback aggregating to ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only), and is within permitted limits. The Company confirms that as required under Section 68(2)(d) of the Companies Act and Regulation 4(i) of Buyback Regulations, the ratio of the aggregate of secured and unsecured debts owed by the Company shall not be more than twice the fully paid-up share capital and free reserves on both standalone and consolidated basis after the Buyback.

1.5 The Buyback shall be on a proportionate basis from all the Equity Shareholders of the Company through the "Tender Offer" route, as prescribed under Regulation 4(iv)(a) of the Buyback Regulations. Please see paragraph 12 below for details regarding record date and share entitlement for tender in the Buyback.

1.6 A copy of this Public Announcement is available on the Company's website www.ajantapharma.com, and is expected to be available on the website of SEBI www.sebi.gov.in and on the website of Stock Exchanges i.e., www.bseindia.com and www.nseindia.com during the period of the Buyback.

2. NECESSITY FOR BUYBACK

The Buyback is the acquisition by a company of its own shares. Buyback is an efficient form of returning surplus cash, which are over and above its ordinary capital requirements and in excess of any current investment plans to the members holding equity shares of the company, in an expedient, efficient and cost effective manner. Additionally, the Company's management strives to increase the Equity Shareholders' value and the Buyback would result in following benefits, amongst other things:

- The Buyback would help in improving Earnings Per Share (EPS), Return on Equity (ROE), Return on Capital Employed (ROCE);
- The Buyback will help in achieving optimal capital structure;
- The Buyback will help the Company to distribute surplus cash to the Equity Shareholders broadly in proportion to their shareholding, thereby, enhancing their overall return;
- The Buyback, which is being implemented through the tender offer route as prescribed under the Buyback Regulations, would involve allocation of number of shares as per the entitlement of the shareholders or 15% of the number of Equity Shares to be bought back whichever is higher, reserved for the small shareholders. The Company believes that this reservation for small shareholders would benefit a large number of public shareholders, who would get classified as "small shareholder" as per 2(i)(n) of the Buyback Regulations;
- The Buyback gives an option to Equity Shareholders to either (i) choose to participate and get cash in lieu of Equity Shares to be accepted under the Buyback offer or (ii) choose not to participate and enjoy a resultant increase in their percentage shareholding, post the Buyback offer, without any additional investment.

After considering the above mentioned factors and benefits to the Equity Shareholders, the Board decided to recommend Buyback of not exceeding 7,35,000 (Seven Lakh Thirty Five Thousand) Equity Shares (representing 0.84% of the total number of equity shares in the paid-up share capital of the Company) at a price of ₹ 1,850/- (Rupees One Thousand Eight Hundred and Fifty only) per Equity Share for an aggregate consideration of not exceeding ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only) excluding any taxes payable under Income Tax Act, 1961 and any expenses incurred or to be incurred for the Buyback, which represents 5.52% and 5.26% of the aggregate of the Company's paid-up capital and free reserves as per the audited financial statements of the Company as on March 31, 2020 on a standalone and consolidated basis, respectively.

3. MAXIMUM NUMBER OF SECURITIES THAT THE COMPANY PROPOSES TO BUYBACK

The Company is proposing to buyback up to 7,35,000 (Seven Lakh Thirty Five Thousand) fully paid-up equity shares of face value of ₹ 2 each representing 0.84% of the total number of Equity Shares in the total paid-up share capital of the Company (calculated on the basis of the total paid-up share capital of the Company as on October 31, 2020).

4. BUYBACK PRICE AND BASIS OF DETERMINING THE PRICE OF THE BUYBACK

4.1 The Buyback offer price of ₹ 1,850/- (Rupees One Thousand Eight Hundred and Fifty only) per Equity Share has been arrived at after considering various factors such as the average closing prices of the Equity Shares on the Stock Exchanges where the Equity Shares of the Company are listed, the net-worth of the Company and the impact of the Buyback on the key financial ratios of the Company.

4.2 The Buyback Offer Price of ₹ 1,850/- (Rupees One Thousand Eight Hundred and Fifty only) per Equity Share represents: (i) premium of 16.80% on BSE and 16.72% on NSE over the volume weighted average price of the Equity Shares on BSE and NSE respectively for 3 months preceding the date of intimation to the BSE and NSE for the Board Meeting to consider the proposal of the Buyback; (ii) premium of 17.40% on BSE and 17.29% on NSE over the volume weighted average price of the Equity Shares on BSE and NSE respectively for 2 weeks preceding the date of intimation to the BSE and NSE for the Board Meeting to consider the proposal of the Buyback; (iii) premium of 16.39% on BSE and 16.23% on NSE over the closing market price of the Equity Shares on BSE and NSE as on the date of the intimation to BSE and NSE for the Board Meeting to consider the proposal of the Buyback.

5. MAXIMUM AMOUNT REQUIRED UNDER THE BUYBACK AND ITS PERCENTAGE OF THE TOTAL PAID-UP CAPITAL AND FREE RESERVES

- The maximum amount required for Buyback will not exceed ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only) excluding Transaction Cost.
- The maximum amount mentioned aforesaid represents 5.52% and 5.26% of the aggregate of the Company's paid-up capital and free reserves as per the audited financial statements of the Company as on March 31, 2020 on a standalone and consolidated basis, respectively.
- The funds for the Buyback will be met out of internally generated cash resources of the Company or such other source as may be permitted by the Buyback Regulations or the Companies Act.
- The funds borrowed, if any from banks and financial institutions will not be used for the Buyback.

6. METHOD TO BE ADOPTED FOR THE BUYBACK

The method to be adopted for the purpose of the Buyback shall be through the Tender Offer route as prescribed under the Buyback Regulations and circulars issued thereunder, including the "Mechanism for acquisition of shares through Stock Exchange" notified by the SEBI Circulars, or such other mechanism, for the Buy Back through Tender Offer route, as may be applicable. Please refer to Paragraph 12 below for details regarding the Record Date and shareholders entitlement for tender in the Buyback.

7. DETAILS OF PROMOTERS SHAREHOLDING AND OTHER DETAILS

7.1 The aggregate shareholding of the promoters and members of the promoter group (collectively referred to as the "Promoters and Promoter Group") and persons who are in control of the Company; directors of the promoter and member of promoter group, where such promoter or member of promoter group is a company; and the Directors and Key Managerial Personnel of the Company as on the date of the Board Meeting i.e. Tuesday, November 3, 2020 is given below:

i. Shareholding of the Promoters and Promoter Group and person in control of the Company:

Sr. No.	Name of shareholder	No. of Equity Shares held	No. of Equity Shares held in dematerialized form	Percentage (%) of issued Equity Share capital
1.	Yogesh Agrawal, trustee Yogesh Agrawal Trust	1,26,39,934	1,26,39,934	14.48
2.	Rajesh Agrawal, trustee Rajesh Agrawal Trust	1,26,39,933	1,26,39,933	14.48
3.	Aayush Agrawal, trustee Aayush Agrawal Trust	1,25,40,389	1,25,40,389	14.37
4.	Ravi Agrawal, trustee Ravi Agrawal Trust	1,25,45,180	1,25,45,180	14.38
5.	Gabs Investments Private Limited	83,92,262	83,92,262	9.62
6.	Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal	23,90,903	23,90,903	2.74
7.	Ravi Agrawal	1,90,000	1,90,000	0.22
8.	Mannalal Agrawal	1,70,000	1,70,000	0.19
9.	Aayush Agrawal	20,000	20,000	0.02
Total		6,15,28,601	6,15,28,601	70.50

ii. Shareholding of directors of the Promoters and Promoter Group entity (i.e. Gabs Investment Private Limited ("GIPL")) in the Company:

Sr. No.	Name	Designation in GIPL	No. of Equity Shares held in the Company	Percentage (%) of issued Equity Share capital
1.	Yogesh Agrawal	Director	1,35,36,523 ⁽¹⁾	15.51
2.	Rajesh Agrawal	Director	1,35,36,522 ⁽²⁾	15.51
3.	Ravi Agrawal	Director	1,33,32,906 ⁽³⁾	15.28
4.	Aayush Agrawal	Director	1,25,60,389 ⁽⁴⁾	14.39
Total			5,29,66,340	60.69

(1): 1,26,39,934 Equity Shares held in capacity as trustee of Yogesh Agrawal Trust and 8,96,589 Equity Shares as partner of Ganga Exports, where the partner's share being 37.5%.
(2): 1,26,39,933 Equity Shares held in capacity as trustee of Rajesh Agrawal Trust and 8,96,589 Equity Shares as partner of Ganga Exports, where the partner's share being 37.5%.
(3): 1,25,45,180 Equity Shares held in capacity as trustee of Ravi Agrawal Trust, 1,90,000 Equity Shares held in individual name in the Company and 5,97,726 Equity Shares as partner of Ganga Exports, where the partners' share being 25.0%.
(4): 1,25,40,389 Equity Shares held in capacity as trustee of Aayush Agrawal Trust and 20,000 Equity Shares held in individual name in the Company.

Apart from the above, no other directors of the entities forming part of the Promoters and Promoter Group as disclosed in 7.1(i) above, hold Equity Shares in the Company.

iii. Shareholding of the Directors and Key Managerial Personnel of the Company:

Sr. No.	Name	Designation	No. of Equity Shares held	Percentage (%) of issued Equity Share capital
1.	Yogesh Agrawal	Managing Director	1,35,36,523 ⁽¹⁾	15.51
2.	Rajesh Agrawal	Joint Managing Director	1,35,36,522 ⁽²⁾	15.51
3.	Mannalal Agrawal	Chairman	1,70,000	0.19
4.	Arvind Agrawal	Chief Financial Officer	26,484	0.03
5.	Gaurang Shah	Company Secretary	1,000	Negligible
6.	Chandrakant Khelan	Independent Director	700	Negligible
Total			2,72,71,229	31.25%

(1): 1,26,39,934 Equity Shares held in capacity as trustee of Yogesh Agrawal Trust and 8,96,589 Equity Shares as partner of Ganga Exports, where the partners' share being 37.5%.
(2): 1,26,39,933 Equity Shares held in capacity as trustee of Rajesh Agrawal Trust and 8,96,589 Equity Shares as partner of Ganga Exports, where the partners' share being 37.5%.

Apart from the above, none of the Directors or Key Managerial Personnel of the Company hold any Equity Shares in the Company.

7.2 No Equity Shares or other specified securities in the Company have been either purchased or sold (either through the Stock Exchanges or off market transactions) by Promoters and Promoter Group and persons who are in control of the Company; directors of the promoter and member of promoter group, where such promoter or member of promoter group is a company; and the Directors and Key Managerial Personnel of the Company during a period of six months preceding the date of the Board Meeting and from the date of Board Meeting till the date of Public Announcement, other than the following:

Aggregate number of Equity Shares purchased or (sold)	Nature of Transaction	Maximum Price (₹)	Date of Maximum Price	Minimum Price (₹)	Date of Minimum Price
Mannalal Agrawal					
1,70,000	Refer Note	Not Applicable	September 18, 2020	Not Applicable	September 18, 2020
Gaurang Shah					
100	Open market purchase	1,444.44	August 31, 2020	1,444.44	August 31, 2020

Note: Distribution of shares by the Mannalal Agrawal Trust to beneficiary of the Trust i.e. Mannalal Agrawal

7.3 Intention of Promoters and Promoter Group to participate in the Buyback:

In terms of the Buyback Regulations, under the Tender Offer route, the promoter and members of promoter group of the Company have an option to participate in the Buyback. In this regard, certain members of the Promoters and Promoter Group as listed in paragraph 7.1(i) above have expressed their intention, vide their letters, each dated November 3, 2020 to participate in the Buyback and tender up to an aggregate maximum number of 89,90,903 (Eighty Nine Lakh Ninety Thousand Nine Hundred Three) Equity Shares or such lower number of Equity Shares as required in compliance with Buyback Regulations.

Sr. No.	Name of shareholder	No. of Equity Shares held	Maximum number of Equity Shares intended to tender
1.	Yogesh Agrawal, trustee Yogesh Agrawal Trust	1,26,39,934	13,00,000
2.	Rajesh Agrawal, trustee Rajesh Agrawal Trust	1,26,39,933	13,00,000
3.	Aayush Agrawal, trustee Aayush Agrawal Trust	1,25,40,389	22,00,000
4.	Ravi Agrawal, trustee Ravi Agrawal Trust	1,25,45,180	18,00,000
5.	Gabs Investments Private Limited	83,92,262	NIL
6.	Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal	23,90,903	23,90,903
7.	Ravi Agrawal	1,90,000	NIL
8.	Mannalal Agrawal	1,70,000	NIL
9.	Aayush Agrawal	20,000	NIL
Total		6,15,28,601	89,90,903

7.4 Since the entire shareholding of the Promoters and Promoter Group who intends to participate in the Buyback is in the demat mode, the details of the date and price of acquisition/ sale of entire Equity Shares that the participating Promoters and Promoter Group has acquired/sold till date as per the information provided by Promoters and Promoter Group, each vide their letter dated November 3, 2020, are set-out below:

Date of Transaction	No. of Equity Shares	Acquisition/ Sale Consideration	Nature of Transaction/Consideration
Yogesh Agrawal, trustee Yogesh Agrawal Trust			
March 23, 2017	1,27,49,999	Gift	Inter-se transfer of Equity Shares from Vimal Mannalal Agrawal
March 22, 2019	(1,10,065)	₹ 14.29 ⁽¹⁾ crores	Tendered in buyback offer of the Company
Total	1,26,39,934		
Rajesh Agrawal, trustee Rajesh Agrawal Trust			
March 22, 2017	1,27,49,999	Gift	Inter-se transfer of Equity Shares from Mannalal Agrawal
March 22, 2019	(1,10,066)	₹ 14.29 ⁽¹⁾ crores	Tendered in buyback offer of the Company
Total	1,26,39,933		
Aayush Agrawal, trustee Aayush Agrawal Trust			
March 27, 2017	1,26,60,000	Gift	Inter-se transfer of Equity Shares from Purushottam Agrawal
March 22, 2019	(1,19,611)	₹ 15.53 ⁽¹⁾ crores	Tendered in buyback offer of the Company
Total	1,25,40,389		
Ravi Agrawal, trustee Ravi Agrawal Trust			
March 24, 2017	1,26,59,999	Gift	Inter-se transfer of Equity Shares from Madhusudan Agrawal
March 22, 2019	(1,14,819)	₹ 14.84 ⁽¹⁾ crores	Tendered in buyback offer of the Company
Total	1,25,45,180		
Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal			
March 31, 2006	6,85,000	NIL	Inter-se transfer of Equity Shares from Vimal P. Agrawal, Samata P. Agrawal and Mamta P. Agrawal
August 10, 2012	13,70,000		Split of Equity Shares from face value of ₹10 to ₹5
September 19, 2013	6,85,000	NIL	Bonus issue of Equity Shares in the ratio of 1:2
March 23, 2015	51,37,500		Split of Equity Shares from face value of ₹5 to ₹2
July 10, 2017	(2,15,000)	₹ 33.33 crores	Market sale
July 11, 2017	(24,85,000)	₹ 372.77 crores	Market sale
March 22, 2019	(46,597)	₹ 6.05 ⁽¹⁾ crores	Tendered in buyback offer of the Company
Total	23,90,903		

⁽¹⁾Net of brokerage charges.

8. NO DEFAULTS

The Board confirms that the Company has not defaulted in the repayment of the deposits accepted either before or after the commencement of the Companies Act, interest payment thereon, redemption of debentures or preference shares or payment of dividend to any shareholder or repayment of any term loan or interest payable thereon to any financial institutions or banking company.

9. CONFIRMATION BY THE BOARD OF DIRECTORS

The Board has confirmed on the date of Board Meeting (i.e. Tuesday, November 3, 2020) that it has made a full enquiry into the affairs and prospects of the Company and has formed an opinion that:

- Immediately following the date of the Board Meeting, there will be no grounds on which the Company could be found to be unable to pay its debts;
- As regards the Company's prospects for the year immediately following date of the Board Meeting and having regard to the Board's intentions with respect to the management of the Company's business during that year and to the amount and character of the financial resources which will in the Board's view be available to the Company during that year, the Company will be able to meet its liabilities as and when they fall due and will not be rendered insolvent within a period of one year from that date of Board Meeting; and
- In forming the opinion, the Board has taken into account the liabilities as if the Company were being wound up under the provisions of the Companies Act 1956 or Companies Act 2013 and Insolvency and Bankruptcy Code 2016, as the case may be (including prospective and contingent liabilities).

10. REPORT BY THE COMPANY'S STATUTORY AUDITOR

The text of the report dated November 3, 2020 received from B S R & Co. LLP, Chartered Accountants, the statutory auditor of the Company, addressed to the Board of Directors of the Company is reproduced below:

Quote

"The Board of Directors
The Ajanta Pharma Limited
Ajanta House, 98 Govt Industrial Area, Kandivli (W)
MUMBAI 400 067

3 November 2020

Dear Sirs

Independent Auditors' Report in respect of proposed buy-back of equity shares by Ajanta Pharma Limited in terms of clause (xi) of Schedule I of Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended

- This report is issued in accordance with the terms of our engagement letter dated 9 July 2018 and addendum to engagement letter dated 25 October 2020 with Ajanta Pharma Limited ("the Company").
- The Board of Directors of the Company have approved a proposed buy-back of equity shares by the Company at its meeting held on 3 November 2020, in pursuance of the provisions of Section 68, 69 and 70 of the Companies Act, 2013 ("the Act") read with the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended ("SEBI Buy-back Regulations"). The accompanying Statement of permissible capital payment (including premium) ("Annexure A") as at 31 March 2020 (hereinafter referred as the "Statement") is prepared by the management of the Company, which we have initiated for identification purpose only.

Management's Responsibility for the Statement

- The preparation of the Statement in accordance with Section 68(2) of the Act and in compliance with Section 68, 69 and 70 of the Act and SEBI Buy-back Regulations, is the responsibility of the Management of the Company, including the computation of the amount of the permissible capital payment, the preparation and maintenance of all accounting and other relevant supporting records and documents. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the Statement and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.

Auditors' Responsibility

- Pursuant to the requirements of the SEBI Buy-back Regulations, it is our responsibility to provide reasonable assurance whether:
 - we have inquired into the state of affairs of the Company in relation to its latest audited standalone and audited consolidated financial statements as at and for the year ended 31 March 2020;

- the amount of permissible capital payment (including premium) as stated in Annexure A for the proposed buy-back of equity shares has been properly determined considering the audited standalone financial statements and audited consolidated financial statements in accordance with Section 68(2) of the Act; and
- the Board of Directors of the Company in their meeting dated 3 November 2020, have formed the opinion as specified in clause (x) of Schedule I to the SEBI Buy-back Regulations on reasonable grounds and that the Company will not, having regard to its state of affairs, be rendered insolvent within a period of one year from that date.

Auditors' Responsibility (Continued)

- The audited standalone financial statements and audited consolidated financial statements referred to in paragraph 5 above, which we have considered for the purpose of this report, have been audited by us, on which we have issued an unmodified audit opinion vide our reports dated 20 May 2020.
- Our engagement involves performing procedures to obtain sufficient appropriate evidence on the above reporting. The procedures selected depend on the auditor's judgement, including the assessment of the risks associated with the above reporting. We accordingly performed the following procedures:
 - Examined that the amount of permissible capital payment (including premium) for the buy-back as detailed in Annexure A is in accordance with the provisions of Section 68(2) of the Act;
 - Inquired into the state of affairs of the Company with reference to the audited standalone financial statements and audited consolidated financial statements as at and for the period ended 31 March 2020;
 - Traced the amounts of paid-up equity share capital, retained earnings and General Reserves as mentioned in Annexure A from the audited standalone financial statements and audited consolidated financial statements as at and for the year ended 31 March 2020;
 - Verified the arithmetical accuracy of the amounts mentioned in Annexure A; and
 - We have obtained appropriate representations from the Management of the Company.
- We conducted our examination of the Statement in accordance with the Guidance Note on Reports or Certificates for Special Purposes (Revised 2016) issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.
- We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements.
- We have no responsibility to update this report for events and circumstances occurring after the date of this report.

Opinion


- Based on inquiries conducted and our examination as above, we report that:
 - We have inquired into the state of affairs of the Company in relation to its audited standalone financial statements and audited consolidated financial statements as at and for the year ended 31 March 2020;
 - The amount of permissible capital payment towards the proposed buy-back of equity shares as computed in the Statement attached herewith is, in our view properly determined in accordance with Section 68(2) of the Act. The amounts of share capital and free reserves have been extracted from the audited standalone financial statements and audited consolidated financial statements of the Company as at and for the year ended 31 March 2020; and

Opinion (Continued)

- The Board of Directors of the Company, in their meeting held on 3 November 2020 have formed their opinion as specified in clause (x) of Schedule I to the SEBI Buy-back Regulations, on reasonable grounds and that the Company, having regard to its state of affairs, will not be rendered insolvent within a period of one year from the date of passing the Board meeting resolution dated 3 November 2020.
- Based on the representations made by the management, and other information and explanations given to us, which to the best of our knowledge and belief were necessary for this purpose, we are not aware of anything to indicate that the opinion expressed by the Directors in the declaration as to any of the matters mentioned in the declaration is unreasonable in circumstances as at the date of declaration.


Restriction on Use

- This report has been issued at the request of the Company solely for use of the Company (i) in connection with the proposed buy-back of equity shares of the Company in pursuance to the provisions of Sections 68 and other applicable provisions of the Act and SEBI



नफ़्फ़ी 50

Company	Close (₹)				PE				Close (₹)				WT			
	4 Nov '20	% Chg	1Y	5Y	4 Nov '20	% Chg	1Y	5Y	4 Nov '20	% Chg	1Y	5Y	4 Nov '20	% Chg	1Y	5Y
Adani Ports	361.1	2.1	0.5	19.1	37.8	IOC	78.0	-0.1	0.7	-	-	-	13.9			
Asian Paints	2169.5	0.7	19	91.5	92.2	ITC	169.8	-0.2	4.0	13.7	14.6	-				
Axata Bank	525.2	-1.7	2.6	86.7	50.8	JSW Steel	317.9	1.0	0.8	0.92	31.0	-				
Bajaj Auto	263.1	0.0	0.7	15.4	2.4	JSW Bank	1539.7	0.0	0.0	1.0	1.0	-				
Bajaj Finserv	3561.5	2.0	1.8	40.2	5.0	L & T	939.9	-0.8	2.5	11.6	11.4	-				
Bajaj Finserv	3561.5	2.0	1.8	40.2	5.0	Maruti Suzuki	596.8	0.2	1	584.0	-	-				
Bharti Airtel	348.9	-0.6	0.7	24.8	17.9	NTPC	699.1	0.6	1.7	37.0	52.8	-				
Birla	3470.7	2.0	0.8	46.6	48.6	ONGC	85.1	-0.1	0.8	7.3	8.2	-				
Britannia	781.2	2.9	0.8	38.3	28.2	Power Grid	67.5	-1.6	0.9	8.4	8.9	-				
Cash	114.8	0.5	114.8	0.5	114.8	191.2	3.4	0.0	0.0	1.0	1.0	-				
Cipla	3196.2	3.4	0.8	61.6	51.3	SBI	207.0	1.1	5.6	8.6	11.3	-				
Dr Reddys	4935.6	1.2	1.1	51.0	33.4	SBI Life	791.0	0.3	0.6	-	49.1	-				
Eicher Motors	221.0	0.8	0.3	4.0	3.7	Shree Cement	2910.4	0.2	0.6	-	59.1	-				
Grasim Ind	83.4	-0.7	0.3	4.0	3.7	Sun Pharma	90.0	0.0	1.9	82.3	40.0	-				
HCL Tech	783.1	-0.6	1.0	15.0	64.5	Tata Motors	135.9	1.3	0.5	-	-	-				
HDFC Bank	812.1	0.1	1.7	18.1	22.5	Tata Steel	403.9	-0.7	0.6	-	7.1	-				
HDFC Bank	812.1	0.1	1.7	18.1	22.5	Tata Tea	255.2	0.2	0.3	20.1	39.4	-				
HDFC Bank	1257.4	0.8	10.3	25.4	24.3	Tech Mahindra	826.9	2.3	5.0	1.9	1.9	-				
HDFC Bank	594.3	-0.8	0.9	92.5	89.6	Titan Company	1215.7	1.3	1.0	17.9	142.8	-				
Hindustan	206.0	0.7	0.5	10.5	10.5	UltraTech	4331.6	-0.4	1.0	21.8	23.5	-				
Hindalco	176.5	-1.8	0.5	16.5	11.2	Wipro	401.4	-0.8	0.0	3.1	112.7	-				
India Cements	676.1	4.9	0.8	18.9	18.9	Nifty 50	11908.5	0.0	100.0	25.2	27.6	-				
Indus Bank	694.1	3.0	7.7	26.1	28.0							-				



मार्केट ओवरव्यू							
INDEX	PE	SHRS	TRDS	1 YR			
C/5	ADJ	ADG	ADV	DEC	RETURNS		
SENSEX	25.9/28.2	2.09	397	20	10	0.8	
NIFTY 50	25.2/27.6	667.3	7133	32	18	-0.3	
C = CONSOLIDATED; S = STANDALONE							
CASH				DERIVATIVES			
TURNOVER		INSE					
VALUE (IN ₹ CRORE)	4126	56536				- 2497876	
SHARES (IN MN)	2476	1916.3				- 502.1	
TRADES (00000)	1717	14641				- 18242	
MARKET-CAP (₹ CR)				TRADED		TOTAL	
BSE	15,916,220				16,997,500		
NSE	15,738,802				15,889,694		
DERIVATIVES	11,821,404				11,821,404		
काठमाडौं गतिविधि							
₹ (CRORE)		ETC				ME	

	Equity Net	Debt Net	Equity Net	Debt Net
On 03 Nov	1543	1576	-	-
On 08 Nov	856	355	-52	971
On 24 Oct	-149	489	467	58
On 28 Oct	872	-640	52	1156
On 27 Oct	3589	-1027	-1491	1483
Nov till date	2399	1221	-52	971
2020 till date	50187	-104901	2619	179503

	Index Net	Stock Index	Index Net	Index Stock
On 03 Nov	1511	718	0.1	0.8
On 02 Nov	-527	829	0.1	0.7
On 28 Oct	-932	817	0.2	1.1
On 30 Oct	-4301	1749	0.1	0.5
On 30 Oct	-3831	1325	0.2	1.2
Nov till date	984	1546	-	-
2020 till date	124599	101	-	-

(The number of contracts in million)

	Prevcls	Close	% Chng
Auto	17,732.5	17,841.9	0.6
Bank	28,447.9	29,554.9	0.4
Cons. Durables	24,306.5	24,654.1	1.5
Comp. Peripherals	14,362.4	14,498.3	0.9
M&G	10,942.7	10,976.5	0.3
Healthcare	19,343.8	19,590.2	1.3
High Tech	141.0	141.3	0.2
Media	20,889.3	21,270.7	1.8
Telecom	8,397.6	8,396.7	-0.6
Oil & Gas	11,803.8	11,880.4	0.6
Power	1,742.2	1,736.5	-0.3
Real Estate	4,663.8	4,650.2	-0.3
Health	1,813.8	1,779.3	-1.9

एफएंडओ स्क्वैशॉर्ट

	Futures price	Cash price	Premium %		Futures price	Cash price	Discount %		
MOST BULLISH									
Vodafone Idea	8.4	8.4	0.6	PVR	1095.2	1116.0	-1.5		
Adani Ports	363.2	361.1	0.6	Petronet LNG	223.3	226.0	-1.2		
Piramal Ent	1310.3	1303.0	0.6	Power Grid	175.4	177.1	-0.9		
SBI	208.1	207.0	0.6	Marico	308.2	371.4	-0.6		
M & M Fin	127.4	126.7	0.6	Shriram Tr Fin	784.4	789.0	-0.6		
MOST BEARISH									
पुट-कॉल रेशियो									
	BSE		NSE						
	Index	Stock	Index	Stock					
FUTURE									
Contracts	-	625875	918168		Market	578.3	974.5	0.6	
Open Int.(000)	-	13123	1537428						
Options (Mn)	-	26.7	1677.1		Top 5	PC Ratio	Bottom 5	PC Ratio	
Shares (Mn)	-	6504	64283		Havells	1.1	Info Edge	0.0	
TOP 5					Indusbank Bank	1.1	Shree Cement	0.1	
Havells		1.1	Info Edge		Kotak Mah Bank	1.0	NITL Techments	0.1	
Indusbank Bank		1.1	Shree Cement		Bajaj Fin	1.0	Ramco Cement	0.1	
Kotak Mah Bank		1.0	NITL Techments		Chola Inv	0.9	SRF	0.2	
Bajaj Fin		1.0	Ramco Cement						
Chola Inv		0.9	SRF						

Company	Daily Volume	2-week Avg Volume	Change %	Close price	*Price %chg
to Rama S	5144487.0	224931.7	22771.4	24.6	4.9
U-I and	1590856.0	278611.6	5611.1	0.5	19.5
India	705717.0	21394.4	319.8	28.3	8.4
Arts	121026.0	4108.5	2845.8	26.6	29.9
erating	3873688.0	224277.3	1627.2	35.2	20.0
stasundev	249374.0	17721.6	1307.1	118.5	21.9
Port	5982680.0	6274708.4	82.8	38.2	11.5
fishan Poly	456829.0	77134.4	74.5	4.4	3.4
ent Refract	344950.0	45725.2	654.4	193.6	2.6
turnbine	263345.0	32562.4	646.8	71.2	3.6

Price		Price		Price	
Company	Price	Company	Price	Company	Price
2250	SH	25.3	"Face 3 Auto	LOW	"Standard Ind
2250	Avin Fluo	64.5	"Likhanti Cons	BSJ 200	"S&S Power SW
2290.0		43.1	Rishipour	NONE	"Neel Ind
2329	"Vivanza Bios	43.1	"Seven Techno	33.0	"Vipari Securiti
2339	Mewar Hi	800.5	2339	"Square Four	5.9
2349	"Bafna Pharma	196.7	Tulive Develop	196.7	"Green W
2359	"Sunedion Int	114.0	"G&P India	114.0	"Pamfari
2360	"Aplo Th	52.0	"Artemis Elect	52.0	"Colorships New
3243.0	RHS BS Serv	31.1	"Shriram Asset	42.9	"HSL
3280.0	Chandra Pr	20.0	"Shrinivas Dev	20.0	"H&S
4500	Jeevan Scent	26.6	Radix Inds	34.3	"NNTL
3740	"Mod Insul	21.2	Jump Network	36.6	"RTFL
3750	"M & P Purkhi	20.0	"Union Inds	20.0	"M&P
3760	Glafida Fin	20.6	Nam Securities	38.0	"Incon Emerg
3760	"Sanchit Corp	29.3	Phosphate Co	29.3	"Trident Tool
3780	"Orchid Pharma	18.3	"Nandani	18.3	"TCS
3790	Sadhana N	18.3	"Sadhana N	18.3	"Suncity Syst
113.0	Aakash Spintex	18.4	"Delta Manufactu	17.0	"Next Media
113.0	Pudumpe Paper	18.4	"Chait Group	18.4	"M&S
80.9	CCCL Int	16.7	Interactive FI	16.7	"Lords Is
80.9	Hemo Organic	16.2	"Harish Text	12.7	"Tramway Tech
75.0	"Betros Greenw	12.2	"Medhil Text	12.2	"Sun India
75.0	Longview Tea	13.3	"K&H Emerg	13.3	"NMS Impex Globa
68.0	"Khandel, Ent	13.4	"Garg Furnace	10.6	"Sudal Ind
62.7	Mayookh Disc	12.9	"Real Eco-Energy	9.9	"Mecon Inds
62.5	"Com Inf	12.1	"Sambhar Text	8.8	"Olympic card

* Indicates that the market price of these companies reached two-year highs

दिन में सबसे ज्यादा चढ़े

Company	Day's high	Close	% chg*	3mth high	52 wk high
L&T Tech Ser	174.53	1731.8	6.0	1879.0	1879.0
A&K Inds	27.22	22.2	5.0	44.6	61.4
680099	6781.9	6781.9	4.8	7101.7	1596.4
Navin Fluor	2593.0	2419.6	4.0	2503.0	2503.0
Sun Pharma	518.2	504.3	4.0	564.9	564.9
Avanta Supermar	2365.2	2291.8	3.8	2484.0	2559.0
30CEI	380.0	380.0	3.8	378.5	378.5
Avanti Feeds	485.0	479.9	3.6	548.7	769.9
Adani Gas	212.9	230.6	3.5	232.9	232.9
Apollu Tyres	149.3	147.9	3.5	152.6	187.6
192989	1913.5	1913.5	3.5	2358.7	2358.7
Shriram Trfn	792.5	789.0	3.4	792.8	1331.8
Divis Lab	3208.8	3194.2	3.4	3388.0	3388.0
171ntech	3037.0	3037.0	3.4	3151.2	3151.2
Page Inds	20362.3	20324.9	3.3	22274.7	26891.0

दिन में सबसे ज्यादा गिरा

Company	Day's low	Close	% chg*	3mth low	52 wk low
Equitas Hold	40.4	41.5	-7.1	40.4	32.8
Godrej Propy	965.0	978.3	-57	821.1	960.0
Indiabulls Mobile	989.1	989.1	-5.0	625.0	975.0
Laurus Labs	270.1	277.2	-4.8	198.7	619.0
UPL	399.0	401.2	-3.8	399.0	240.3
Advanced Enzyme	286.3	284.5	-3.4	196.1	91.1
Vedanta	91.3	91.9	-3.1	88.0	77.0
Muthoot Finance	1137.3	1157.2	-2.8	1000.0	477.5
Aditya Birla Fy	147.3	148.2	-2.7	117.2	96.5
BHEL	27.0	27.2	-2.7	26.8	19.2
26868	181.0	181.0	-2.6	175.0	111.0
LHC Hsg Fin	292.5	295.4	-2.3	255.6	186.0
Emami	365.8	371.6	-2.2	256.3	140.9
2087.0	2087.0	-2.0	1623.0	1473.0	
InterGlobe Avia	1341.1	1341.1	-2.0	928.0	765.1

* Ranked on the basis of percentage gain/loss on previous close

सबसे ज्यादा कारोबार

प्रमुख ड्रम-केप

रुझान

Value	Volume	Rank	Company	MCQA (FY 17)	Company	% change	Company	% change
(₹ crore)	BSE-NSE (Mn shrs)							
		1	Reliance Ind	12130144	BS200		Saven Techno	33.32
		2	TCS	2956045.5	HCX		TCI	32.72
Reliance Ind	7207.4	38.1	HDFC Bank	6927278.9	UP1 DAYS		Source Natural	14.5
Sun Pharma	2516.9	49.5	HUL	484851.7	DOWN	14.7	DOWN 7 DAYS	
SBI	2508.6	122.8	Infosys	465905.5	Equitas Hold		Jayswark Jew	-33.7
IndusInd Bank	2444.3	36.6	Kotak Mah Bank	374936.1	Vital Fabrics	-15.6	Jumply In	-36.7
Adani Ports	2055.4	58.0	ICICI Bank	326145.2	UP1 DAYS		Durpy In	-23.7
ICICI Bank	1965.6	45.2	Blart Airtel	216053.2	Shriram Trfn	-15.8	Malhindra EPC	-14.3
Infosys	1779.7	16.2	HCL Techno	222673.2	Hawells I	10.8	Vijay Solvs	-13.2
Bajaj Fin	1577.2	42.5	ITC	214486.4	SBI	10.8	CHD Chemicals	-14.2
Axis Bank	1540.2	29.7	Maruti Suzuki	200112.1	Sun Pharma	8.2	IZMO	-22.7
HDFC Bank	1525.7	12.2	ITC	208815.9	Bank of Baroda	8.2	UP1 DAYS	
TCFS	1347.0	5.0	Asian Paints	208704.5	Landus Bank		10.1	21.1
HDFC	1121.3	5.4	Wipro	159404.5	DOWN		Careerwing	22.6
Kotak Mah Bank	851.7	16	SBI	184783.4	Bondans Labs	-13.2	KCI Metals	19.3
HCL Techno	850.6	10.3	Nestle India	163871.6	UP1 DAYS	-11.5	Amala Solvs	19.5
UPL	797.2	19.7	Avenue Supermar	144652.7	Advanced Enzyme	-6.8	Alakshdeep Metal	16.9
Rd Reddys	783.6	16	L & T	131402.7	Strides Pharma	-6.5	RPEL	15.7
Cipla	773.3	9.5	Adani Green En	131948.7	Aarti Drugs	-6.1	8K Mills Software	15.1
GMR	686.9	22.2	Ultra Tech	133961.3	Vsanti Org	-5.1	DOWN 3 DAYS	
Maruti Suzuki	665.2	49.1	Sun Pharma	120996.7	Others	-4.9	Khalit Chem	-13.4
Tata Motors	652.9	23.4	HDFC Std Life	120064.6	UP1 DAYS		Zenotech Lab	-12.7
Tata Steel	617.2	25	Titan Company	107891.0	Jet Airways		Nucleus Soft	-12.7
Hero MotoCorp	579.2	14.3	Power Grid	92655.1	Remid Edil	-4.1	Sharat Indus	-12.6
Wipro	545.2	19	Bajaj Finsrv	92593.2	Nuneson Ind	39.8	Bajaj Healthcare	-12.5
Asian Paints	494.2	23	Dind Zinc	90358.0	Vivanza Bios	36.0	Radhey Trade Har	-12.3
Blart Airtel	494.1	10.9	Divis Lab	84750.0				

(+/-) 360seconds which resellert continuous

Indices	Close	% Chg*	Indices	Close	% Chg*
Americas (Nov 03,20)			Asia/Pacific (Nov 04,20)		
Dow Jones	27480.0	2.1	Taiwan Tseix	12687.9	1.0
Nasdaq Composite	11160.6	1.8	Strails Times	2516.8	0.6
S&P/TSX Composite	15939.2	0.5	Kospi	2357.3	0.6
Europe/Africa (Nov 03,20)			Kuala Lumpur Comp	1464.6	0.2
CAC 40	4839.1	0.7	Shanghai Se Comp	3277.4	0.2
Euro Stoxx 50	12146.1	0.5	Stock Exchange of Thai	61.12242	0.1
TSE 100	5814.1	0.5	Jakarta Composite	5165.2	-1.1
BSE SENSEX	6711.0	-0.6	Volatility (Nov 03,20)		
Asia/Pacific (Nov 03,20)			CBSE S&P 500	34.9	-1.9
Nikkei 225	23695.2	1.7	CBDO Dow Jones	32.6	-4.4
TOPIX	2096.7	0.7			

* Change in % from previous close

	Previous Close	Open	High	Low	Close	Change	% chng
S&P BSE Sensex	40,261.1	40,171.7	40,693.5	40,076.5	40,616.1	355.0	0.9
S&P BSE Sense 500	12,375.2	12,354.4	12,498.5	12,319.5	12,477.3	102.1	0.8
BSE-100	11,888.1	11,872.5	12,003.9	11,838.6	11,986.3	98.2	0.8
BSE-200	4,976.1	4,970.7	5,022.5	4,956.0	5,015.6	39.5	0.8
BSE-500	15,394.9	15,381.0	15,528.5	15,334.4	15,508.3	113.4	0.7
BSE IPO	6,753.4	6,723.7	6,784.1	6,720.4	6,770.7	17.4	0.3
Dollx-30	4,443.0				4,452.8	9.8	0.2
Nifty 50	11,813.5	11,783.4	11,929.7	11,756.4	11,908.5	95.0	0.8
Nifty next50	27,603.6	27,674.0	27,810.6	27,550.8	27,784.8	184.8	0.7
Nifty 500	9,696.3	9,684.1	9,778.1	9,654.6	9,764.6	68.3	0.7
India VIX	24.2	24.2	24.2	20.7	23.2	-1.0	-4.3
Nifty CPSE	1,336.6	1,339.2	1,339.4	1,314.4	1,326.3	-10.3	-0.8
MXE S&K 40	23,530.0	23,530.0	23,724.7	23,530.0	23,724.7	194.7	0.8

favour of the Company. (iv) self-attested copy of PAN Card(s) of all Equity Share documents such as power of attorney, corporate authorization (including board resolution), self-attested copy of death certificate and succession certificate or probated will, deceased, etc., as applicable. In addition, if the address of the Equity Shareholder from the address registered in the register of Members of the Company is not Aadhar card, voter identity card or passport.

b. Based on these documents, the concerned Shareholder Broker shall place and Shareholders holding Physical Shares who wish to tender Equity Shares in the window of NSE. Upon placing the bid, the Shareholder Broker shall provide an bidding system to the Equity Shareholder. TRS will contain the details of order no., distinctive no., no. of Equity Shares tendered etc.

any Shareholder or prospective Shareholder who practices a uniform policy that the Shareholder or prospective Shareholder does not place bids in the Share Buyback bidding system upon placing a bid, either by registered post, speed post or by hand, to the Buyback Offer i.e. Link Intime India Private Limited (at the end of 14 below) not later than 2 (two) days from the offer closing date. The envelope to be submitted to the Registrar shall be marked as follows:

"Ajanta Pharma Limited - Buyback Offer 2020". One copy of the TRS will be submitted to the Registrar and it will provide acknowledgement of the same to the Shareholder.

Equity Shareholders holding physical Equity Shares should note that physical Equity Shares will not be accepted for the Buyback Offer unless the complete set of documents is submitted. Acceptance of the physical Equity Shares for the Buyback Offer is subject to verification of the documents by the Company shall be subject to verification as per the Buyback Regulations. In this regard, The Registrar to the Buyback Offer will verify such bids based on a daily basis and till such verification, NSE shall display such bids as 'unconfirmed'. If the Shareholder's bid is not accepted for the Buyback Offer, the Shareholder will be able to bid to the Buyback Offer confirms the bids, they will be treated as 'confirmed bids'.

11.11 METHOD OF SETTLEMENT

Upon finalization of the basis of acceptance as per Buyback Regulations:

- The Company will pay consideration to Company's Broker who will transfer the funds to the Clearing Corporation's bank account as per the prescribed schedule. For the Buyback, the Equity Shareholders will receive funds pay-out in their Bank/Current Corporation.
- The Demat Shares bought back would be transferred directly to the demat account of the Buyer for the Buyback (the "**Company Demat Account**") provided it is indicated by the demat participant to be transferred by the Company's Broker to the Company Demat account on the clearing and settlement mechanism of the NSE.
- The Eligible Equity Shareholders will have to ensure that they keep the depositor's bank account unblocked to receive credit in case of return of Demat Shares, due to rejection by the NSE.
- Excess Demat Shares or unaccepted Demat Shares, if any, tendered by the Shareholder would be returned to them by the Clearing Corporation. Any excess Physical Shares accepted/ rejection will be returned back to the concerned Eligible Shareholder to the Buyback. The Company is authorized to split the share certificate and issue a certificate for the unaccepted Physical Shares, in case the Physical Shares are less than the Physical Shares tendered in the Buyback.
- The settlement of fund obligation for Demat and Physical Shares shall be effected as and as prescribed by NSE and Clearing Corporation from time to time. For Demat Buyback, such beneficial owners will receive funds payout in their bank account through the system directly to the Clearing Corporation and in case of Physical Shares, the funds to the Shareholder Broker(s) as per secondary market payout mechanism. Demat bank account details are not available or if the funds transfer instruction is in India ("RBI") bank(s), due to any reasons, then the amount payable to the Shareholder will be transferred to the Shareholder Broker for onward transfer to such shareholder's bank account.
- In case of certain shareholders viz., NRIs, non-residents etc. (where there are restrictions on funds repatriation) which are not represented by the RBI (where there are



सिडबी

भारतीय लघु उद्योग विकास बैंक

आरएफपी सूचना

सेडबी इच्छुक एजेंसियों से विषयगत हीज खास मैट्रो स्टेशन मेपेटा लाइन-लाइन 8) की सी-ड्राइंग के लिए (आरएफपी) आमंत्रित करता है।

प्रस्तुत निविदा दर्तावेज के लिए कृपया हमारी वेबसाइट www.sidi.in या www.eprocure.gov.in/cppp का अवलोकन करें।

अभिलेखित प्रस्तुत करने की अंतिम तिथि नवम्बर 30, 2020 है।

एडिशनल/शुद्धिपत्र, यदि कोई हुआ तो, केवल उपर्युक्त वेबसाइट पर ही प्रकाशित किया जाएगा।

नोटिस **www**
वेबसाइटों प
दिनांक: 4th
स्थान: नई

.....

हाउसिंग एंड अर्बन डेवलपमेंट कॉर्पोरेशन लिमिटेड
(गैर सरकारी को अफ़ेयर्स)
CIN: L74899DL1970CO005276 GST No.: 07AAACH6632A1ZF
पंजीकृत कार्यालय: इंदौर स्थान, इंदौर सिटी डिस्ट्रिक्ट स्टेशन
लोकरी रोड, नई दिल्ली-110003, दूरभाष: (दिल्ली/गैरदिल्ली) 011-24649610, 24648106
फैक्स नं.: +91-(011)-24615343, ई-मेल: csw@hudco@hudco.org वेबसाइट: www.hudco.org

नोटिस

ते और विनिमय बोर्ड (सूचीबद्धता बाध्यताएं और प्रकटीकरण अपेक्षाएं) के नियम 47 के साथ पठित नियम 29 के अनुपालन में एतद द्वारा जारी है कि 30 सितंबर, 2020 को सामान्य लिहाई एवं छमाही के लिए खाशेरीशित वित्तीय परिणामों (एकल एवं समकालिक) पर विचार करने कोमत के लिए हाउसिंग एंड अर्बन डेवलपमेंट कॉर्पोरेशन लिमिटेड के की बैठक का आयोजन 12 नवम्बर, 2020 को किया जाएगा।

www.hudco.org, www.bseindia.com और www.nseindia.com
को उपलब्ध है।

कृते हाउसिंग एंड अर्बन डेवलपमेंट कॉर्पोरेशन लिमिटेड
हस्ता /
हरीश कुमार सावंत
कंपनी सचिव

नवम्बर, 2020
ली

.....

की जाएगी। सहायक महाप्रबंधक

The image shows the logo of Mirza International Limited, which consists of a stylized 'M' and 'I' inside a circle. Below the logo, the company name 'MIRZA INTERNATIONAL LIMITED' is written in a bold, serif font. Underneath the name, the contact details are listed: 'CIN : L19129UP1979PLC004821', 'Regd. Off. : 14/6, Civil Lines, Kanpur - 208001', and 'website : www.mirza.co.in ; e-mail : priyanka_pahuja@redtapeindia.com'. Below this, the text 'Tel. : +91 512 2530775' is displayed. A large, bold, black 'NOTICE' is centered on the page. The notice text, in a serif font, states: 'Pursuant to the provisions of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notice is hereby given that 3rd Meeting for the Financial Year 2020-2021 of the Board of Directors of the Company is scheduled to be held on Tuesday, 10th November, 2020 at the Tannery Division of the Company, Unnao Link Road, Magarwara, Unnao- 209801 at 11:30 A.M., to consider and approve, interalia, Standalone and Consolidated Unaudited Financial results together with Segment wise Revenue, Results and Capital Employed for the quarter and half year ended 30th September, 2020 along with Statement of Assets and Liabilities for the half year ended 30th September, 2020. The information contained in this notice is also available on the Company's website at www.mirza.co.in and on the website of the Stock Exchanges where the shares of the Company are listed viz. www.bseindia.com and www.nseindia.com.' At the bottom of the notice, it says 'For Mirza International Limited (Priyanka Pahuja) Company Secretary & Compliance Officer'. The date 'Date: 03.11.2020' is written on the left. The 'RED TAP' logo is at the bottom center, featuring a stylized 'RT' monogram above the words 'RED TAP' in a bold, sans-serif font.



AJANTA PHARMA LIMITED

CIN : L24230MH1979PLC022059

Registered & Corporate Office: 'Ajanta House', 98 Govt Industrial Area, Charkop, Kandivli (West), Mumbai - 400 067, Maharashtra, India

Tel.: +91 22 6606 1000, Fax: +91 22 6606 1200 | E-mail: investor grievance@ajantapharma.com

Website: www.ajantapharma.com

PUBLIC ANNOUNCEMENT FOR THE ATTENTION OF EQUITY SHAREHOLDERS/ BENEFICIAL OWNERS OF EQUITY SHARES OF AJANTA PHARMA LIMITED FOR BUYBACK OF EQUITY SHARES THROUGH TENDER OFFER UNDER THE SECURITIES AND EXCHANGE BOARD OF INDIA (BUY-BACK OF SECURITIES), REGULATIONS, 2018, AS AMENDED.

This Public Announcement (the "Public Announcement") is being made in relation to the Buyback (as defined hereinafter) pursuant to the provisions of Regulation 7(i) and other applicable provisions of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended (the "Buyback Regulations") for the time being in force including any statutory modifications and amendments from time to time and contains the disclosures as specified in Schedule II to the Buyback Regulations read with Schedule I of the Buyback Regulations.

CASH OFFER FOR BUYBACK OF NOT EXCEEDING 7,35,000 (SEVEN LAKH THIRTY FIVE THOUSAND) FULLY PAID UP EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH AT A PRICE OF ₹ 1,850/- (RUPEES ONE THOUSAND EIGHT HUNDRED AND FIFTY ONLY) PER FULLY PAID UP EQUITY SHARE ON A PROPORTIONATE BASIS THROUGH THE TENDER OFFER PROCESS

1. DETAILS OF THE BUYBACK OFFER AND OFFER PRICE

1.1 Pursuant to the resolution passed by the Board of Directors of Ajanta Pharma Limited (the "Company") (the Board of Directors of the Company are hereinafter referred to as the "Board" or the "Board of Directors") on November 3, 2020 ("Board Meeting"), the Company hereby announces the buyback of fully paid-up equity shares of face value of ₹ 2 each ("Shares" or "Equity Shares") of the Company not exceeding 7,35,000 (Seven Lakh Thirty Five Thousand) Equity Shares from the equity shareholders/ beneficial owners of Equity Shares of the Company including the promoter and members of the promoter group (the "Equity Shareholders" / "Shareholders") as on Record Date (as defined hereinafter), on a proportionate basis, through "tender offer" process, in accordance with Article 18 of the Articles of Association of the Company, Section 68, 69 and 70, and other applicable provisions of Companies Act, 2013 including any statutory modification(s) or re-enactment thereof (the "Companies Act"), and applicable rules thereunder including the Companies (Share Capital and Debentures) Rules, 2014, as amended, the Buyback Regulations, at a price of ₹ 1,850/- (Rupees One Thousand Eight Hundred and Fifty only) per Equity Share ("Buyback Price" / "Buyback Offer Price") payable in cash, for an aggregate maximum consideration not exceeding ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only) (the "Buyback Offer Size") (the process being hereinafter referred as the "buyback" / "Buyback Offer"). The Buyback Offer Size and the Buyback Offer Price do not include taxes payable under Income Tax Act, 1961 and any expenses incurred or to be incurred for the Buyback viz., brokerage, turnover charges, taxes such as securities transaction tax and goods and services tax (if any), stamp duty, advisors fees, printing and dispatch expenses and other incidental and related expenses and charges ("Transaction Costs"). The Buyback Offer Size represents 5.52% and 5.26% of the aggregate of the Company's paid-up capital and free reserves as per the audited financial statements of the Company as on March 31, 2020 on a standalone and consolidated basis, respectively.

1.2 The Buyback is in accordance with the provisions of Companies Act, Article 18 of the Articles of Association of the Company, and subject to the provisions of the Buyback Regulations, and such other approvals, permissions as may be required from time to time from BSE Limited (the "BSE") and the National Stock Exchange of India Limited (the "NSE") (BSE and NSE are hereinafter together referred to as the "Stock Exchanges") where the Equity Shares of the Company are listed and from any other statutory and/or regulatory authority, as may be required and which may be agreed to by the Board and/or any committee thereof. The Buyback would be undertaken in accordance with circular bearing number CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015 and circular no. CFD/DCR2/CIR/P/2016/131 dated December 09, 2016, issued by Securities and Exchange Board of India ("SEBI") (the "SEBI Circulars"), which prescribes mechanism for acquisition of shares through stock exchange. In this regard, the Company will request NSE to provide the acquisition window.

1.3 In accordance with the provisions of Companies Act and Buyback Regulations, the Buyback Offer Size of ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only), represents 5.52% and 5.26% of the aggregate of the fully paid-up equity share capital and free reserves as per the audited standalone and consolidated financial statements of the Company for the financial year ended March 31, 2020, respectively (the last audited financial statements available as on the date of the Board Meeting approving the Buyback) and is within the statutory limits of 10% of the aggregate of the fully paid-up equity share capital and free reserves as on March 31, 2020 under the Board of Directors approval route as per the provisions of the Companies Act. Further, under the Companies Act, the number of equity shares that can be bought back in any financial year cannot exceed 25% of the total paid-up equity share capital of a company in that financial year. Since the Company proposes to Buyback up to 7,35,000 (Seven Lakh Thirty Five Thousand) Equity Shares representing 0.84% of the total number of Equity Shares in the total paid-up share capital of the Company (calculated on the basis of the total paid-up share capital of the Company as on October 31, 2020), the same is within the aforesaid 25% limit.

1.4 The maximum amount required by the Company for the said Buyback aggregating to ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only), and is within permitted limits. The Company confirms that as required under Section 68(2)(d) of the Companies Act and Regulation 4(ii) of Buyback Regulations, the ratio of the aggregate of secured and unsecured debts owed by the Company shall not be more than twice the fully paid-up share capital and free reserves on both standalone and consolidated basis after the Buyback.

1.5 The Buyback shall be on a proportionate basis from all the Equity Shareholders of the Company through the "Tender Offer" route, as prescribed under Regulation 4(iv)(a) of the Buyback Regulations. Please see paragraph 12 below for details regarding record date and share entitlement for tender in the Buyback.

1.6 A copy of this Public Announcement is available on the Company's website www.ajantapharma.com, and is expected to be available on the website of SEBI www.sebi.gov.in and on the website of Stock Exchanges i.e., www.bseindia.com and www.nseindia.com during the period of the Buyback.

2. NECESSITY FOR BUYBACK

The Buyback is the acquisition by a company of its own shares. Buyback is an efficient form of returning surplus cash, which are over and above its ordinary capital requirements and in excess of any current investment plans to the members holding equity shares of the company, in an expedient, efficient and cost effective manner. Additionally, the Company's management strives to increase the Equity Shareholders' value and the Buyback would result in following benefits, amongst other things:

i. The Buyback would help in improving Earnings Per Share (EPS), Return on Equity (ROE), Return on Capital Employed (ROCE);

ii. The Buyback will help in achieving optimal capital structure;

iii. The Buyback will help the Company to distribute surplus cash to the Equity Shareholders broadly in proportion to their shareholding, thereby, enhancing their overall return;

iv. The Buyback, which is being implemented through the tender offer route as prescribed under the Buyback Regulations, would involve allocation of number of shares as per the entitlement of the shareholders or 15% of the number of Equity Shares to be bought back whichever is higher, reserved for the small shareholders. The Company believes that this reservation for small shareholders would benefit a large number of public shareholders, who would get classified as "small shareholder" as per 2(i)(n) of the Buyback Regulations;

v. The Buyback gives an option to Equity Shareholders to either (i) choose to participate and get cash in lieu of Equity Shares to be accepted under the Buyback offer or (ii) choose not to participate and enjoy a resultant increase in their percentage shareholding, post the Buyback offer, without any additional investment.

After considering the above mentioned factors and benefits to the Equity Shareholders, the Board decided to recommend Buyback of not exceeding 7,35,000 (Seven Lakh Thirty Five Thousand) Equity Shares (representing 0.84% of the total number of equity shares in the paid-up share capital of the Company) at a price of ₹ 1,850/- (Rupees One Thousand Eight Hundred and Fifty only) per Equity Share for an aggregate consideration of not exceeding ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only) excluding any taxes payable under Income Tax Act, 1961 and any expenses incurred or to be incurred for the Buyback, which represents 5.52% and 5.26% of the aggregate of the Company's paid-up capital and free reserves as per the audited financial statements of the Company as on March 31, 2020 on a standalone and consolidated basis, respectively.

3. MAXIMUM NUMBER OF SECURITIES THAT THE COMPANY PROPOSES TO BUYBACK

The Company is proposing to buyback up to 7,35,000 (Seven Lakh Thirty Five Thousand) fully paid-up equity shares of face value of ₹ 2 each representing 0.84% of the total number of Equity Shares in the total paid-up share capital of the Company (calculated on the basis of the total paid-up share capital of the Company as on October 31, 2020).

4. BUYBACK PRICE AND BASIS OF DETERMINING THE PRICE OF THE BUYBACK

4.1 The Buyback offer price of ₹ 1,850/- (Rupees One Thousand Eight Hundred and Fifty only) per Equity Share has been arrived at after considering various factors such as the average closing prices of the Equity Shares on the Stock Exchanges where the Equity Shares of the Company are listed, the net-worth of the Company and the impact of the Buyback on the key financial ratios of the Company.

4.2 The Buyback Offer Price of ₹ 1,850/- (Rupees One Thousand Eight Hundred and Fifty only) per Equity Share represents: (i) premium of 16.80% on BSE and 16.72% on NSE over the volume weighted average price of the Equity Shares on BSE and NSE respectively for 3 months preceding the date of intimation to the BSE and NSE for the Board Meeting to consider the proposal of the Buyback; (ii) premium of 17.40% on BSE and 17.29% on NSE over the volume weighted average price of the Equity Shares on BSE and NSE respectively for 2 weeks preceding the date of intimation to the BSE and NSE for the Board Meeting to consider the proposal of the Buyback; (iii) premium of 16.39% on BSE and 16.23% on NSE over the closing market price of the Equity Shares on BSE and NSE as on the date of the intimation to BSE and NSE for the Board Meeting to consider the proposal of the Buyback.

5. MAXIMUM AMOUNT REQUIRED UNDER THE BUYBACK AND ITS PERCENTAGE OF THE TOTAL PAID-UP CAPITAL AND FREE RESERVES

5.1 The maximum amount required for Buyback will not exceed ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only) excluding Transaction Cost.

5.2 The maximum amount mentioned aforesaid represents 5.52% and 5.26% of the aggregate of the Company's paid-up capital and free reserves as per the audited financial statements of the Company as on March 31, 2020 on a standalone and consolidated basis, respectively.

5.3 The funds for the Buyback will be met out of internally generated cash resources of the Company or such other source as may be permitted by the Buyback Regulations or the Companies Act.

5.4 The funds borrowed, if any from banks and financial institutions will not be used for the Buyback.

6. METHOD TO BE ADOPTED FOR THE BUYBACK

The method to be adopted for the purpose of the Buyback shall be through the Tender Offer route as prescribed under the Buyback Regulations and circulars issued thereunder, including the "Mechanism for acquisition of shares through Stock Exchange" notified by the SEBI Circulars, or such other mechanism, for the Buy Back through Tender Offer route, as may be applicable. Please refer to Paragraph 12 below for details regarding the Record Date and shareholders entitlement for tender in the Buyback.

7. DETAILS OF PROMOTERS SHAREHOLDING AND OTHER DETAILS

7.1 The aggregate shareholding of the promoters and members of the promoter group (collectively referred to as the "Promoters and Promoter Group") and persons who are in control of the Company, directors of the promoter and member of promoter group, where such promoter or member of promoter group is a company; and the Directors and Key Managerial Personnel of the Company as on the date of the Board Meeting i.e. Tuesday, November 3, 2020 is given below:

i. Shareholding of the Promoters and Promoter Group and person in control of the Company:

Sr. No.	Name	No. of Equity Shares held	No. of Equity Shares held in dematerialized form	Percentage (%) of issued Equity Share capital
1.	Yogesh Agrawal, trustee Yogesh Agrawal Trust	1,26,39,934	1,26,39,934	14.48
2.	Rajesh Agrawal, trustee Rajesh Agrawal Trust	1,26,39,933	1,26,39,933	14.48
3.	Aayush Agrawal, trustee Aayush Agrawal Trust	1,25,40,389	1,25,40,389	14.37
4.	Ravi Agrawal, trustee Ravi Agrawal Trust	1,25,45,180	1,25,45,180	14.38
5.	Gabs Investments Private Limited	83,92,262	83,92,262	9.62
6.	Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal	23,90,903	23,90,903	2.74
7.	Ravi Agrawal	1,90,000	1,90,000	0.22
8.	Mannalal Agrawal	1,70,000	1,70,000	0.19
9.	Aayush Agrawal	20,000	20,000	0.02
Total		6,15,28,601	6,15,28,601	70.50

ii. Shareholding of directors of the Promoters and Promoter Group entity (i.e. Gabs Investment Private Limited ("GIPL")) in the Company:

Sr. No.	Name	Designation in GIPL	No. of Equity Shares held in the Company	Percentage (%) of issued Equity Share capital
1.	Yogesh Agrawal	Director	1,35,36,523 ⁽¹⁾	15.51
2.	Rajesh Agrawal	Director	1,35,36,522 ⁽²⁾	15.51
3.	Ravi Agrawal	Director	1,33,32,906 ⁽³⁾	15.28
4.	Aayush Agrawal	Director	1,25,60,389 ⁽⁴⁾	14.39
Total			5,29,66,340	60.69

(1): 1,26,39,934 Equity Shares held in capacity as trustee of Yogesh Agrawal Trust and 8,96,589 Equity Shares as partner of Ganga Exports, where the partner's share being 37.5%.

(2): 1,26,39,933 Equity Shares held in capacity as trustee of Rajesh Agrawal Trust and 8,96,589 Equity Shares as partner of Ganga Exports, where the partner's share being 37.5%.

(3): 1,25,45,180 Equity Shares held in capacity as trustee of Ravi Agrawal Trust, 1,90,000 Equity Shares held in individual name in the Company and 5,97,726 Equity Shares as partner of Ganga Exports, where the partners' share being 25.0%.

(4): 1,25,40,389 Equity Shares held in capacity as trustee of Aayush Agrawal Trust and 20,000 Equity Shares held in individual name in the Company.

Apart from the above, no other directors of the entities forming part of the Promoters and Promoter Group as disclosed in 7.1(i) above, hold Equity Shares in the Company.

iii. Shareholding of the Directors and Key Managerial Personnel of the Company:

Sr. No.	Name	Designation	No. of Equity Shares held	Percentage (%) of issued Equity Share capital
1.	Yogesh Agrawal	Managing Director	1,35,36,523 ⁽¹⁾	15.51
2.	Rajesh Agrawal	Joint Managing Director	1,35,36,522 ⁽²⁾	15.51
3.	Mannalal Agrawal	Chairman	1,70,000	0.19
4.	Arvind Agrawal	Chief Financial Officer	26,484	0.03
5.	Gaurang Shah	Company Secretary	1,000	Negligible
6.	Chandrakant Khelan	Independent Director	700	Negligible
Total			2,72,71,229	31.25%

(1): 1,26,39,934 Equity Shares held in capacity as trustee of Yogesh Agrawal Trust and 8,96,589 Equity Shares as partner of Ganga Exports, where the partners' share being 37.5%.

(2): 1,26,39,933 Equity Shares held in capacity as trustee of Rajesh Agrawal Trust and 8,96,589 Equity Shares as partner of Ganga Exports, where the partners' share being 37.5%.

Apart from the above, none of the Directors or Key Managerial Personnel of the Company hold any Equity Shares in the Company.

7.2 No Equity Shares or other specified securities in the Company have been either purchased or sold (either through the Stock Exchanges or off market transactions) by Promoters and Promoter Group and persons who are in control of the Company; directors of the promoter and member of promoter group, where such promoter or member of promoter group is a company; and the Directors and Key Managerial Personnel of the Company during a period of six months preceding the date of the Board Meeting and from the date of Board Meeting till the date of Public Announcement, other than the following:

Aggregate number of Equity Shares purchased or (sold)	Nature of Transaction	Maximum Price (₹)	Date of Maximum Price	Minimum Price (₹)	Date of Minimum Price
Mannalal Agrawal					
1,70,000	Refer Note	Not Applicable	September 18, 2020	Not Applicable	September 18, 2020
Gaurang Shah					
100	Open market purchase	1,444.44	August 31, 2020	1,444.44	August 31, 2020

Note: Distribution of shares by the Mannalal Agrawal Trust to beneficiary of the Trust i.e. Mannalal Agrawal

Intention of Promoters and Promoter Group to participate in the Buyback:

In terms of the Buyback Regulations, under the Tender Offer route, the promoter and members of promoter group of the Company have an option to participate in the Buyback. In this regard, certain members of the Promoters and Promoter Group as listed in paragraph 7.1(i) above have expressed their intention, vide their letters, each dated November 3, 2020 to participate in the Buyback and tender up to an aggregate maximum number of 89,90,903 (Eighty Nine Lakh Ninety Thousand Nine Hundred Three) Equity Shares or such lower number of Equity Shares as required in compliance with Buyback Regulations.

Sr. No.	Name of shareholder	No. of Equity Shares held	Maximum number of Equity Shares intended to tender
1.	Yogesh Agrawal, trustee Yogesh Agrawal Trust	1,26,39,934	13,00,000
2.	Rajesh Agrawal, trustee Rajesh Agrawal Trust	1,26,39,933	13,00,000
3.	Aayush Agrawal, trustee Aayush Agrawal Trust	1,25,40,389	22,00,000
4.	Ravi Agrawal, trustee Ravi Agrawal Trust	1,25,45,180	18,00,000
5.	Gabs Investments Private Limited	83,92,262	NIL
6.	Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal	23,90,903	23,90,903
7.	Ravi Agrawal	1,90,000	NIL
8.	Mannalal Agrawal	1,70,000	NIL
9.	Aayush Agrawal	20,000	NIL
Total		6,15,28,601	89,90,903

7.4 Since the entire shareholding of the Promoters and Promoter Group who intends to participate in the Buyback is in the demat mode, the details of the date and price of acquisition/ sale of entire Equity Shares that the participating Promoters and Promoter Group has acquired/sold till date as per the information provided by Promoters and Promoter Group, each vide their letter dated November 3, 2020, are set-out below:

Date of Transaction	No. of Equity Shares	Acquisition/ Sale Consideration	Nature of Transaction/Consideration
Yogesh Agrawal, trustee Yogesh Agrawal Trust			
March 23, 2017	1,27,49,999	Gift	Inter-se transfer of Equity Shares from Vimal Mannalal Agrawal
March 22, 2019	(1,10,065)	₹ 14.29 ⁽¹⁾ crores	Tendered in buyback offer of the Company
Total	1,26,39,934		
Rajesh Agrawal, trustee Rajesh Agrawal Trust			
March 22, 2017	1,27,49,999	Gift	Inter-se transfer of Equity Shares from Mannalal Agrawal
March 22, 2019	(1,10,066)	₹ 14.29 ⁽¹⁾ crores	Tendered in buyback offer of the Company
Total	1,26,39,933		
Aayush Agrawal, trustee Aayush Agrawal Trust			
March 27, 2017	1,26,60,000	Gift	Inter-se transfer of Equity Shares from Purushottam Agrawal
March 22, 2019	(1,19,611)	₹ 15.53 ⁽¹⁾ crores	Tendered in buyback offer of the Company
Total	1,25,40,389		
Ravi Agrawal, trustee Ravi Agrawal Trust			
March 24, 2017	1,26,59,999	Gift	Inter-se transfer of Equity Shares from Madhusudan Agrawal
March 22, 2019	(1,14,819)	₹ 14.84 ⁽¹⁾ crores	Tendered in buyback offer of the Company
Total	1,25,45,180		
Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal			
March 31, 2006	6,85,000	NIL	Inter-se transfer of Equity Shares from Vimal P. Agrawal, Samata P. Agrawal and Mamta P. Agrawal
August 10, 2012	13,70,000		Split of Equity Shares from face value of ₹10 to ₹5
September 19, 2013	6,85,000	NIL	Bonus issue of Equity Shares in the ratio of 1:2
March 23, 2015	51,37,500		Split of Equity Shares from face value of ₹5 to ₹2
July 10, 2017	(2,15,000)	₹ 33.33 crores	Market sale
July 11, 2017	(24,85,000)	₹ 372.77 crores	Market sale
March 22, 2019	(46,597)	₹ 6.05 ⁽¹⁾ crores	Tendered in buyback offer of the Company
Total	23,90,903		

⁽¹⁾Net of brokerage charges.

8. NO DEFAULTS

The Board confirms that the Company has not defaulted in the repayment of the deposits accepted either before or after the commencement of the Companies Act, interest payment thereon, redemption of debentures or preference shares or payment of dividend to any shareholder or repayment of any term loan or interest payable thereon to any financial institutions or banking company.

9. CONFIRMATION BY THE BOARD OF DIRECTORS

The Board has confirmed on the date of Board Meeting (i.e. Tuesday, November 3, 2020) that it has made a full enquiry into the affairs and prospects of the Company and has formed an opinion that:

a) Immediately following the date of the Board Meeting, there will be no grounds on which the Company could be found to be unable to pay its debts;

b) As regards the Company's prospects for the year immediately following date of the Board Meeting and having regard to the Board's intentions with respect to the management of the Company's business during that year and to the amount and character of the financial resources which will in the Board's view be available to the Company during that year, the Company will be able to meet its liabilities as and when they fall due and will not be rendered insolvent within a period of one year from that date of Board Meeting; and

c) In forming the opinion, the Board has taken into account the liabilities as if the Company were being wound up under the provisions of the Companies Act 1956 or Companies Act 2013 and Insolvency and Bankruptcy Code 2016, as the case may be (including prospective and contingent liabilities).

10. REPORT BY THE COMPANY'S STATUTORY AUDITOR

The text of the report dated November 3, 2020 received from B S R & Co. LLP, Chartered Accountants, the statutory auditor of the Company, addressed to the Board of Directors of the Company is reproduced below:

Quote

"The Board of Directors
The Ajanta Pharma Limited
Ajanta House, 98 Govt Industrial Area, Kandivli (W)
MUMBAI 400 067

3 November 2020

Dear Sirs

Independent Auditors' Report in respect of proposed buy-back of equity shares by Ajanta Pharma Limited in terms of clause (xi) of Schedule I of Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended

1. This report is issued in accordance with the terms of our engagement letter dated 9 July 2018 and addendum to engagement letter dated 25 October 2020 with Ajanta Pharma Limited ("the Company").

2. The Board of Directors of the Company have approved a proposed buy-back of equity shares by the Company at its meeting held on 3 November 2020, in pursuance of the provisions of Section 68, 69 and 70 of the Companies Act, 2013 (the "Act") read with the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended ("SEBI Buy-back Regulations"). The accompanying Statement of permissible capital payment (including premium) (Annexure A) as at 31 March 2020 (hereinafter referred as the "Statement") is prepared by the management of the Company, which we have initiated for identification purpose only.

Management's Responsibility for the Statement

3. The preparation of the Statement in accordance with Section 68(2) of the Act and in compliance with Section 68, 69 and 70 of the Act and SEBI Buy-back Regulations, is the responsibility of the Management of the Company, including the computation of the amount of the permissible capital payment, the preparation and maintenance of all accounting and other relevant supporting records and documents. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the Statement and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.

Auditors' Responsibility

4. Pursuant to the requirements of the SEBI Buy-back Regulations, it is our responsibility to provide reasonable assurance whether:

i. we have inquired into the state of affairs of the Company in relation to its latest audited standalone and audited consolidated financial statements as at and for the year ended 31 March 2020;

ii. the amount of permissible capital payment (including premium) as stated in Annexure A for the proposed buy-back of equity shares has been properly determined considering the audited standalone financial statements and audited consolidated financial statements in accordance with Section 68(2) of the Act; and the Board of Directors of the Company in their meeting dated 3 November 2020, have formed the opinion as specified in clause (x) of Schedule I to the SEBI Buy-back Regulations on reasonable grounds and that the Company will not, having regard to its state of affairs, be rendered insolvent within a period of one year from that date.

Auditors' Responsibility (Continued)

5. The audited standalone financial statements and audited consolidated financial statements referred to in paragraph 5 above, which we have considered for the purpose of this report, have been audited by us, on which we have issued an unmodified audit opinion vide our reports dated 20 May 2020.

6. Our engagement involves performing procedures to obtain sufficient appropriate evidence on the above reporting. The procedures selected depend on the auditor's judgement, including the assessment of the risks associated with the above reporting. We accordingly performed the following procedures:

i. Examined that the amount of permissible capital payment (including premium) for the buy-back as detailed in Annexure A is in accordance with the provisions of Section 68(2) of the Act;

ii. Inquired into the state of affairs of the Company with reference to the audited standalone financial statements and audited consolidated financial statements as at and for the period ended 31 March 2020;

iii. Traced the amounts of paid-up equity share capital, retained earnings and general Reserves as mentioned in Annexure A from the audited standalone financial statements and audited consolidated financial statements as at and for the year ended 31 March 2020;

iv. Verified the arithmetical accuracy of the amounts mentioned in Annexure A; and

v. We have obtained appropriate representations from the Management of the Company.

7. We conducted our examination of the Statement in accordance with the Guidance Note on Reports or Certificates for Special Purposes' (Revised 2016) issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.

8. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements.

9. We have no responsibility to update this report for events and circumstances occurring after the date of this report.

Opinion

10. Based on inquiries conducted and our examination as above, we report that:

a) We have inquired into the state of affairs of the Company in relation to its audited standalone financial statements and audited consolidated financial statements as at and for the year ended 31 March 2020;

b) The amount of permissible capital payment towards the proposed buy-back of equity shares as computed in the Statement attached herewith is, in our view properly determined in accordance with Section 68(2) of the Act. The amounts of share capital and free reserves have been extracted from the audited standalone financial statements and audited consolidated financial statements of the Company as at and for the year ended 31 March 2020; and

Opinion (Continued)

c) The Board of Directors of the Company, in their meeting held on 3 November 2020 have formed their opinion as specified in clause (x) of Schedule I to the SEBI Buy-back Regulations, on reasonable grounds and that the Company, having regard to its state of affairs, will not be rendered insolvent within a period of one year from the date of passing the Board meeting resolution dated 3 November 2020.

11. Based on the representations made by the management, and other information and explanations given to us, which to the best of our knowledge and belief were necessary for this purpose, we are not aware of anything to indicate that the opinion expressed by the Directors in the declaration as to any of the matters mentioned in the declaration is unreasonable in circumstances as at the date of declaration.

Restriction on Use

12. This report has been issued at the request of the Company solely for use of the Company (i) in connection with the proposed buy-back of equity shares of the Company in pursuance to the provisions of Sections 68 and other applicable provisions of the Act and SEBI Buy-back Regulations, (ii) to enable the Board of Directors of the Company to include in the public announcement, draft letter of offer, letter of offer and other documents pertaining to buy-back to be sent to the shareholders of the Company or filed with (a) the Registrar of Companies, Securities and Exchange Board of India, stock exchanges, public shareholders and any other regulatory authority as per applicable law and (b) the Central Depository Services (India) Limited, National Securities Depository Limited and (iii) for providing to the managers, each for the purpose of extinguishment of equity shares and may not be suitable for any other purpose.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022
Sd/-
Sreeja Marar
Partner
Membership No: 111410
UDIN: 20111410AAAAACN9825

Mumbai
3 November 2020

Annexure A – Statement of permissible capital payment (including premium)

Computation of amount of permissible capital payment towards buy back of equity shares of Ajanta Pharma Limited in accordance with proviso to Section 68 (2) of the Companies Act, 2013 (the "Act") and proviso to Regulation 4(i) of the Buyback Regulations :

Particulars	Amount extracted from the latest audited standalone financial statement as at March 31, 2020 Amount in INR crores	Amount extracted from the latest audited consolidated financial statement as at March 31, 2020 Amount in INR crores
Paid up equity share capital (87,261,270 Equity Shares of INR 2 each, fully paid up) [A]	17.54*	17.54*
Free reserves #:		
-General reserve	879.62	951.18
-Retained earnings	1,565.51	1,617.18
Total free reserves [B]	2,445.13	2,568.36
Total [A + B]	2,462.67	2,585.90
Maximum amount permissible for buyback as per the Act and Buyback Regulations (i.e. 10% of aggregate of fully paid up equity share capital and free reserves)	246.27	258.59
Buyback offer size permitted by Board Resolution dated November 3, 2020	135.98	
Buyback offer size as a percentage of total paid up capital and free reserves	5.52%	5.26%

*The amount includes INR 0.09 crores on account of forfeiture of equity shares.

#Free reserves are as per sub clause 43 of Section 2 and explanation II to Section 68 of the Act.

@ Securities premium has not been considered for above calculation as per Companies Act, 2013. However, the same would be utilized for the buyback of shares based on Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018.

For Ajanta Pharma Limited
Sd/-
Arvind Agrawal
Chief Financial Officer

Mumbai
November 3, 2020"

Way2Wealth
WAY2WEALTH BROKERS PRIVATE LIMITED
Address: EFC Office Infra, 14th Floor, A wing, Empire Tower, Reliable Cloud city, Gut No.31, Off-Thane – Belapur Road, Airoli, Navi Mumbai – 400708.
Tel.: 022-40192900 | 61462900; Fax: 022-61462999;
Email: swarna.satam@way2wealth.com; Website: www.way2wealth.com
Contact Person: Ms. Swarna Satam
SEBI Registration Number: INZ000178638
Corporate Identity Number: U67120KA2000PTC027628

11.4 The Company will request NSE to provide a separate acquisition window ("Acquisition Window") to facilitate placing of sell orders by eligible Equity Shareholders who wish to tender Equity Shares in the Buyback. For the purpose of this Buyback, NSE would be the designated stock exchange ("Designated Stock Exchange"). The details of the Acquisition Window will be as specified by NSE from time to time. In the event Shareholder (Broker's) of eligible Equity Shareholder is not registered with NSE, then the eligible Equity Shareholders can approach any NSE registered stock broker and can register themselves by using quick unique client code ("UCC") facility through the NSE registered stock broker (after submitting all details as may be required by such NSE registered stock broker in compliance with applicable law). In case the eligible Equity Shareholders are unable to register using UCC facility through any other NSE registered broker, eligible Equity Shareholders may approach Company's Broker i.e., Way2Wealth Brokers Private Limited to place their bids.

11.5 At the beginning of the tendering period, the order for buying Equity Shares will be placed by the Company through Company's Broker. During the tendering period, the order for selling the Equity Shares will be placed in the acquisition window by eligible Equity Shareholders through their respective stock brokers ("Shareholder Broker") during normal trading hours of the secondary market. The Shareholder Broker can enter orders for Demat Shares as well as Physical Shares. In the tendering process, the Company's Broker may also process the orders received from the eligible Equity Shareholders.

11.6 The reporting requirement of Non-Resident Shareholders under the Foreign Exchange Management Act, 1999 and any other rules, regulations, guidelines, for remittance of funds, shall be made by the eligible Equity Shareholder and/or the Shareholder Broker through which the eligible Equity Shareholder places the bid.

11.7 Modification/ cancellation of orders and multiple bids from a single eligible Equity Shareholder will be allowed during the tendering period of the Buyback. Multiple bids made by a single eligible Equity Shareholder for selling Equity Shares shall be clubbed and considered as "one bid" for the purposes of acceptance.

11.8 The cumulative quantity tendered shall be made available on the website of NSE (www.nseindia.com) throughout the trading session and will be updated at specific intervals during the tendering period.

11.9 Procedure to be followed by eligible Equity Shareholders holding Demat Shares:

a. Equity Shareholders holding Demat Shares who desire to tender their Demat Shares under the Buyback would have to do so through their respective Shareholder Broker by indicating to the concerned Shareholder Broker, the details of Equity Shares they intend to tender under the Buyback.

b. The Shareholder Broker would be required to place an order/bid on behalf of the Shareholders who wish to tender Equity Shares in the Buyback using the acquisition window of the NSE. Before placing the order/bid, the eligible Equity Shareholder would require to transfer the number of Equity Shares tendered to the special account of NSE Clearing Limited ("Clearing Corporation" / "NCL"), by using the early pay in mechanism prior to placing the bid by the Shareholder Broker. The details

